9/124280

```
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1813nxm
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Aug 21   CAS patent coverage expanded
 NEWS  3  Aug 24   TABULATE Now Available in More STN Databases
 NEWS  4  Aug 28   MEDLINE from 1958 to Date - Only on STN
 NEWS  5  Sep  7   DGENE GETSIM ALERT: Similarity Current-Awareness
                   Searching of Biosequences
 NEWS  6  Sep 11   Textile Technology Digest (TEXTILETECH) now available
                   on STN
 NEWS  7  Sep 21   KKF renamed DKILIT
 NEWS  8  Sep 29   The Philippines Inventory of Chemicals and Chemical
                   Substances (PICCS) has been added to CHEMLIST
 NEWS  9  Oct 27   New Extraction Code PAX now available in Derwent
                   Files
 NEWS 10  Oct 27   SET ABBREVIATIONS and SET PLURALS extended in
                   Derwent World Patents Index files
 NEWS 11  Oct 27   Patent Assignee Code Dictionary now available
                   in Derwent Patent Files
 NEWS 12  Oct 27   Plasdoc Key Serials Dictionary and Echoing added to
                   Derwent Subscriber Files WPIDS and WPIX

 NEWS EXPRESS  FREE UPGRADE 5.0D FOR STN EXPRESS 5.0 WITH DISCOVER!
               (WINDOWS) NOW AVAILABLE
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:34:20 ON 30 OCT 2000

=> file embase medline biosis uspatfull japio wpids caplus biotechds agricola


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.30       0.30

FILE 'EMBASE' ENTERED AT 11:35:33 ON 30 OCT 2000
```

FILE 'MEDLINE' ENTERED AT 11:35:33 ON 30 OCT 2000

FILE 'BIOSIS' ENTERED AT 11:35:33 ON 30 OCT 2000

FILE 'USPATFULL' ENTERED AT 11:35:33 ON 30 OCT 2000

FILE 'JAPIO' ENTERED AT 11:35:33 ON 30 OCT 2000

FILE 'WPIDS' ENTERED AT 11:35:33 ON 30 OCT 2000

FILE 'CAPLUS' ENTERED AT 11:35:33 ON 30 OCT 2000

FILE 'BIOTECHDS' ENTERED AT 11:35:33 ON 30 OCT 2000

FILE 'AGRICOLA' ENTERED AT 11:35:33 ON 30 OCT 2000

=> e porro massimo/au

E1	1		PORRO MARCELLO A/AU
E2	5		PORRO MARIA GRAZIA/AU
E3	39	-->	PORRO MASSIMO/AU
E4	2		PORRO MIGUEL E/AU
E5	9		PORRO MONICA/AU
E6	1		PORRO N/AU
E7	1		PORRO NICHOLAS D/AU
E8	1		PORRO NOEL M/AU
E9	7		PORRO NOVO N/AU
E10	7		PORRO P/AU
E11	1		PORRO PAOLO/AU
E12	11		PORRO R/AU

=> s e3

L1 39 "PORRO MASSIMO"/AU

=> s l1 and sepsis

L2 8 L1 AND SEPSIS

=> dup rem l8

L8 IS NOT VALID HERE
The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> dup rem l2

PROCESSING COMPLETED FOR L2
L3 7 DUP REM L2 (1 DUPLICATE REMOVED)

=> d bib ab 1-7

L3 ANSWER 1 OF 7 CAPLUS

Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions of the invention bind Lipid-A of endotoxins.

L3 ANSWER 4 OF 7 USPATFULL
AN 94:35369 USPATFULL
TI Oligosaccharide conjugate vaccines
IN **Porro, Massimo**, Siena, Italy
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)
PI US 5306492 19940426
AI US 1992-921678 19920730 (7)
RLI Division of Ser. No. US 1990-590649, filed on 28 Sep 1990, now patented, Pat. No. US 5153312
DT Utility
EXNAM Primary Examiner: Kim, Kay K.
LREP Dow, Kenneth J.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular polysaccharide.

A specific embodiment of the invention provides for vaccines which induce immunity to prevalent serotypes of Streptococcus pneumoniae.

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2000 ACS
AN 1993:574225 CAPLUS
DN 119:174225
TI Synthetic peptides for detoxification of bacterial endotoxins and treatment of septic shock
IN **Porro, Massimo**
PA Italy
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9314115	A1	19930722	WO 1992-EP1060	19920514
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MW, NL, NO, RO, RU, SD, SE, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	US 5371186	A	19941206	US 1992-819893	19920116
	AU 9216914	A1	19930803	AU 1992-16914	19920514
	AU 665945	B2	19960125		
	EP 623144	A1	19941109	EP 1992-910229	19920514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	FI 9403396	A	19940715	FI 1994-3396	19940715
PRAI	US 1992-819893	19920116			
	US 1991-658744	19910211			
	WO 1992-EP1060	19920514			

AB The novel peptides are R1-(A-B-C)n-R, wherein R1 and R are independently H or an amino acid residue or a fatty acid residue; A = Lys, Arg, or His; B = Phe, Tyr, or Trp; C = Leu, Ile, or Val; and n = 1-100. The peptides are used for prevention or treatment of septic shock, for the detection of

endotoxin, and for prepn. of a safe antigenic complex of lipid A for producing anti-lipid A antibody.

L3 ANSWER 6 OF 7 USPATFULL
AN 92:82892 USPATFULL
TI Oligosaccharide conjugate vaccines
IN **Porro, Massimo**, Siena, Italy
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)
PI US 5153312 19921006
AI US 1990-590649 19900928 (7)
DT Utility
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Kim, Kay
LREP Dow, Kenneth J.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular polysaccharide.

A specific embodiment of the invention provides for vaccines which induce immunity to prevalent serotypes of Streptococcus pneumoniae.

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2000 ACS
AN 1993:463064 CAPLUS
DN 119:63064
TI Synthetic peptides for detoxification of bacterial endotoxins and for prevention and treatment of septic shock
IN **Porro, Massimo**
PA Italy
SO S. African, 40 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 9200943	A	19921125	ZA 1992-943	19920210

PRAI US 1991-658744 19910211
AB The title peptides, e.g. Lys-Phe-Leu-contg. peptides (I), are effective in the treatment of septic shock by binding with the lipid A moiety of endotoxins. The peptides are also useful as a diagnostic probe for detection and quantitation of endotoxin in blood. The activity of the peptides were confirmed by the direct microprecipitin assay with Bacillus pertussis lipid A and lipopolysaccharide. Actinomycin D-sensitized mice were i.v. treated with I and challenged by i.p. injection of Escherichia coli endotoxin; a survival rate after 7 days was 40%, compared to 30% and 5% for polymixin B-treated control group and saline-treated control group, resp.

=> d his

(FILE 'HOME' ENTERED AT 11:34:20 ON 30 OCT 2000)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, BIOTECHDS, AGRICOLA' ENTERED AT 11:35:33 ON 30 OCT 2000
E PORRO MASSIMO/AU
L1 39 S E3

AN 2000:84285 CAPLUS
DN 132:136410
TI Vaccines for prevention of gram-negative bacterial infections and endotoxin-related diseases
IN **Porro, Massimo**
PA Biosynth S.R.L., Italy
SO Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 976402	A2	20000202	EP 1999-202476	19990727

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRAI US 1998-124280 19980729

AB A vaccine is disclosed which is useful for protecting a host from Gram neg. infections and the effects of endotoxin, therefore preventing **sepsis** and septic shock. The vaccine is prepd. by combining LPS free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)n wherein A is Lysine or Arginine and n is an integer with a min. value of 7; (b) (AB)m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a min. value of 3; and (c) (ABC)p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a min. value of 2.

L3 ANSWER 2 OF 7 BIOSIS COPYRIGHT 2000 BIOSIS DUPLICATE 1
AN 2000:173998 BIOSIS
DN PREV200000173998
TI Influence of synthetic antiendotoxin peptides on Lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14.
AU Iwagaki, Akitaka; **Porro, Massimo**; Pollack, Matthew (1)
CS (1) Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814 USA
SO Infection and Immunity., (March, 2000) Vol. 68, No. 3, pp. 1655-1663. ISSN: 0019-9567.
DT Article
LA English
SL English

AB Lipopolysaccharides (LPS) are proinflammatory bacterial products implicated in the pathogenesis of gram-negative **sepsis** and septic shock. Polymyxin B (PMB), a cyclic, cationic peptide antibiotic, inhibits biological activities of LPS through high-affinity binding to the lipid A moiety. Small synthetic peptides have been designed to mimic the primary and secondary structures of PMB to determine structural requirements for binding and detoxification of lipid A and to assess possible therapeutic potential. The purpose of this study was to compare and contrast the endotoxin-neutralizing activities of two synthetic antiendotoxin peptides (SAEP-2 and SAEP-4), PMB, and an LPS core-specific monoclonal antibody (MAb), WN1 222-5, based on their abilities to inhibit CD14-mediated target cell uptake of fluorescein isothiocyanate (FITC)-conjugated LPS, detected by flow cytometry and confocal microscopy, and LPS-induced production of the proinflammatory cytokines, interleukin-6

(IL-6) and tumor necrosis factor alpha (TNF-alpha), as measured by bioassays. PMB and SAEP-4 produced dose-dependent inhibition of FITC-LPS uptake by CD14-transfected Chinese hamster ovary fibroblasts (CHO-CD14 cells) and by human peripheral blood mononuclear cells. The anti-LPS MAb, WN1 222-5, also blocked LPS uptake by these cells and synergized with PMB and SAEP-4. LPS-induced IL-6 release was inhibited by PMB, SAEP-4, and MAb WN1 222-5, and these inhibitory activities were additive or synergistic. LPS-induced TNF-alpha release by PBMC was also inhibited by PMB and SAEP-4 alone and in combination with anti-LPS MAb. SAEP-2, in contrast, produced comparatively minor decrements in cellular uptake of LPS and LPS-induced cytokine responses, and did so only in the absence of serum, while a nonsense peptide exerted no discernible inhibitory effect on LPS uptake or LPS-induced cytokine expression in the presence or absence of serum. Thus, PMB and SAEP-4, like the LPS-reactive MAb, WN1 222-5, block proinflammatory activities of LPS in part by preventing LPS recognition by membrane-bound CD14-expressing target cells. Differences in peptide structure, however, like those exemplified by SAEP-2 and SAEP-4, may differentially affect the endotoxin-neutralizing potency of these peptides despite similar binding activity against lipid A, reflecting possible differences in peptide solubility or peptide regulation of intracellular signal transduction.

L3 ANSWER 3 OF 7 USPATFULL
AN 97:66100 USPATFULL
TI Peptides for neutralizing the toxicity of Lipid A
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5652211 19970729
AI US 1993-97830 19930726 (8)
RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned , said Ser. No. US -49871 which is a continuation of Ser. No. US -658744
DT Utility
EXNAM Primary Examiner: Russell, Jeffrey E.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 39
ECL Exemplary Claim: 36,38
DRWN No Drawings
LN.CNT 683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is concerned with a peptide composition which includes a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which Is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine,

L2 8 S L1 AND SEPSIS
L3 7 DUP REM L2 (1 DUPLICATE REMOVED)

=> s l1 and lps (5a) peptide

L4 7 L1 AND LPS (5A) PEPTIDE

=> d bib 1-7

L4 ANSWER 1 OF 7 BIOSIS COPYRIGHT 2000 BIOSIS
AN 2000:173998 BIOSIS
DN PREV200000173998
TI Influence of synthetic antiendotoxin peptides on Lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14.
AU Iwagaki, Akitaka; **Porro, Massimo**; Pollack, Matthew (1)
CS (1) Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814 USA
SO Infection and Immunity., (March, 2000) Vol. 68, No. 3, pp. 1655-1663. ISSN: 0019-9567.
DT Article
LA English
SL English

L4 ANSWER 2 OF 7 USPATFULL
AN 1998:138863 USPATFULL
TI Potentiation of antibiotics
IN **Porro, Massimo**, Siena, Italy
Varra, Martti, Haartmaninkatu, Finland
PA BiosYnth S.r.l., Italy (non-U.S. corporation)
PI US 5834430 19981110
AI US 1995-456112 19950531 (8)
DT Utility
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Harle, Jennifer
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 7 USPATFULL
AN 97:66100 USPATFULL
TI Peptides for neutralizing the toxicity of Lipid A
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5652211 19970729
AI US 1993-97830 19930726 (8)
RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned , said Ser. No. US -49871 which is a continuation of Ser. No. US -658744
DT Utility
EXNAM Primary Examiner: Russell, Jeffrey E.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 39
ECL Exemplary Claim: 36,38
DRWN No Drawings
LN.CNT 683

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 7 USPATFULL
AN 96:120869 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)
PI US 5589459 19961231
AI US 1994-280397 19940726 (8)
RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,
Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Davenport, Avis M.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 7 USPATFULL
AN 94:106884 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5371186 19941206
AI US 1992-819893 19920116 (7)
DCD 20111025
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 7 USPATFULL
AN 94:93312 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN **Porro, Massimo**, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5358933 19941025
AI US 1993-49871 19930419 (8)
RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2000 ACS
AN 2000:146841 CAPLUS
DN 132:303016

TI Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14
AU Iwagaki, Akitaka; **Porro, Massimo**; Pollack, Matthew
CS Department of Medicine, Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, MD, 20814, USA
SO Infect. Immun. (2000), 68(3), 1655-1663
CODEN: INFIBR; ISSN: 0019-9567
PB American Society for Microbiology
DT Journal
LA English
RE.CNT 38
RE
(1) Coyne, C; Am J Vet Res 1993, V54, P305 CAPLUS
(2) Demitri, M; J Endotoxin Res 1996, V3, P445 CAPLUS
(3) Di Padova, F; Infect Immun 1993, V61, P3863 CAPLUS
(4) Evans, T; J Infect Dis 1995, V171, P153 CAPLUS
(5) Golenbock, D; J Biol Chem 1993, V268, P22055 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l1 and gram negative bacterial infect?

L5 1 L1 AND GRAM NEGATIVE BACTERIAL INFECT?

=> d bib ab

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2000 ACS
AN 2000:84285 CAPLUS
DN 132:136410
TI Vaccines for prevention of **gram-negative bacterial infections** and endotoxin-related diseases
IN **Porro, Massimo**
PA Biosynth S.R.L., Italy
SO Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 976402	A2	20000202	EP 1999-202476	19990727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI US 1998-124280 19980729
AB A vaccine is disclosed which is useful for protecting a host from Gram neg. infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepd. by combining LPS free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)n wherein A is Lysine or Arginine and n is an integer with a min. value of 7; (b) (AB)m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a min. value of 3; and (c) (ABC)p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a min. value of 2.

=> s bacterial (5a) infect?

L6 157699 BACTERIAL (5A) INFECT?

=> s l6 and lps (5a) peptide

L7 50 L6 AND LPS (5A) PEPTIDE

=> dup rem l7

PROCESSING COMPLETED FOR L7
L8 46 DUP REM L7 (4 DUPLICATES REMOVED)

=> d bib ab 1-46

L8 ANSWER 1 OF 46 USPATFULL
AN 2000:109964 USPATFULL
TI Antimicrobial peptides and methods of use thereof
IN Pereira, H. Anne, Edmond, OK, United States
PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)
PI US 6107460 20000822
AI US 1999-258934 19990301 (9)
DT Utility
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Srivastava, Deven
LREP Dunlap, Codding & Rogers
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1073
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against **bacterial infections** and diseases caused by **bacterial infection**. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.

L8 ANSWER 2 OF 46 USPATFULL
AN 2000:106071 USPATFULL
TI Mammalian cationic proteins having lipopolysaccharide binding and anti-coagulant activity
IN Larrick, James W., Woodside, CA, United States
Wright, Susan C., Saratoga, CA, United States
Hirata, Michimasa, Morioka, Japan
PA Panorama Research, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6103888 20000815
AI US 1999-322911 19990601 (9)
RLI Continuation of Ser. No. US 1996-691280, filed on 1 Aug 1996 which is a continuation-in-part of Ser. No. US 313681
DT Utility
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Portner, Ginny Allen
LREP Townsend and Townsend and Crew
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 30 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the treatment and diagnosis of lipopolysaccharide-related conditions and coagulant-related disease are provided. Compositions include polypeptides which are identical or homologous to a certain cationic protein (CAP18) obtained from mammalian granulocytes, particularly including a reactive nitrogen inhibiting

peptide (RNIP) fragment found at the carboxy-terminus of CAP18. Polypeptides are capable of binding to LPS and inhibiting LPS-mediated activation of macrophage, as well as interfering with the clotting cascade to inhibit coagulation in conditions such as disseminated intravascular coagulation. Compositions comprising the polypeptides in a suitable pharmaceutical carrier are also provided.

L8 ANSWER 3 OF 46 USPATFULL
AN 2000:70809 USPATFULL
TI Method for the treatment of **bacterial infection**
IN Pereira, Heloise Anne, Edmond, OK, United States
PA The Board of Regents of the University of Oklahoma, United States (U.S. corporation)
PI US 6071879 20000606
AI US 1999-260373 19990301 (9)
RLI Continuation of Ser. No. US 1997-840519, filed on 21 Apr 1997, now patented, Pat. No. US 5877151 which is a continuation of Ser. No. US 1995-482328, filed on 7 Jun 1995, now patented, Pat. No. US 5627262, issued on 6 May 1997 which is a continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916 which is a continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Moore, William W.
LREP Dunlap, Codding & Rogers, P.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 806
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention contemplates a composition and method for treating a **bacterial infection** in a mammal.
Comprising/administering a therapeutically effective amount of a peptide derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 or 120-146 of CAP37 or subunits thereof.

L8 ANSWER 4 OF 46 USPATFULL
AN 2000:54074 USPATFULL
TI Antimicrobial cationic peptides
IN Hancock, Robert E. W., Vancouver, Canada
Karunaratne, Nedra, Kandy, Sri Lanka
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 6057291 20000502
AI US 1996-763226 19961210 (8)
RLI Continuation-in-part of Ser. No. US 1996-658857, filed on 31 May 1996 which is a continuation-in-part of Ser. No. US 1995-460464, filed on 2 Jun 1995, now patented, Pat. No. US 5877274
DT Utility
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Longton, Enrique D.
LREP Fish & Richardson P. C.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)

LN.CNT 2740
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH.sub.2 --KWKSFIKKLTTAVKKVLTTGLPALIS--COOH (SEQ ID NO:1) and NH.sub.2 --KWKSFIKKLTSAAKKVVTTAKPLISS--COOH (SEQ ID NO:2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.

L8 ANSWER 5 OF 46 USPATFULL
AN 2000:34679 USPATFULL
TI Antimicrobial cationic peptides
IN Hancock, Robert E. W., Vancouver, Canada
Karunaratne, Nedra, Vancouver, Canada
PA University of British Columbia, Vancover, Canada (non-U.S. corporation)
PI US 6040435 20000321
AI US 1996-658857 19960531 (8)
RLI Continuation-in-part of Ser. No. US 1995-460464, filed on 2 Jun 1995, now patented, Pat. No. US 5877274
DT Utility
EXNAM Primary Examiner: Sisson, Bradley; Assistant Examiner: Longton, Enrique D.
LREP Gary Cary Ware & Freidenrich LLP; Haile, Lisa A.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2069
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include

NH.sub.2 -KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO:1)

and

NH.sub.2 -KWKSFIKKLTSAAKKVVTTAKPLISS-COOH. (SEQ ID NO:2)

Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.

L8 ANSWER 6 OF 46 USPATFULL
AN 2000:34537 USPATFULL
TI Antimicrobial peptide
IN Hirata, Michimasa, Morioka, Japan
PA Seikagaku Corporation, Tokyo, Japan (non-U.S. corporation)
PI US 6040291 20000321
AI US 1999-276202 19990325 (9)
PRAI JP 1998-78136 19980325
JP 1998-176466 19980623
DT Utility
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Knobbe, Martens, Olson & Bear, LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1558
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A peptide comprising at least the following amino acid sequence:

Lys Xa1 Phe Lys Arg Ile Val Xa2 Arg Ile Xaa Xa2 Phe Leu Arg Xa2 Leu Val (SEQ ID NO: 1)

wherein, Xa1 represents a hydrophobic amino acid residue, each of Xa2 independently represents a hydrophilic amino acid residue, and Xaa represents an arbitrary amino acid residue;

an antimicrobial agent, a medicine including a **bacterial infection**-treating agent and an endotoxin shock suppressant which each comprise the peptide as an active ingredient; and an endotoxin-removing agent comprising the peptide immobilized to an insoluble carrier.

L8 ANSWER 7 OF 46 USPATFULL
AN 2000:1857 USPATFULL
TI Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
IN Andersen, Anders Jorgen, Kokkedal, Denmark
Aston, Roger, Wiltshire, United Kingdom
Carlen, Peter Louis, Ontario, Canada
Doob, Penelope Reed, Ontario, Canada
MacFadden, Douglas Kevin, Ontario, Canada
Phipps, David James, Ontario, Canada
Rathjen, Deborah, New South Wales, Australia
Widmer, Fred, New South Wales, Australia
PA Advanced Immunit, Inc., Stony Brook, NY, United States (U.S. corporation)
PI US 6011014 20000104
AI US 1998-82837 19980521 (9)
RLI Continuation of Ser. No. US 302829
DT Utility
EXNAM Primary Examiner: Davenport, Avis M.
LREP Nims, Howes, Collison Hansen & Lackert
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2387
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating or preventing multiple sclerosis in a patients in need of such treatment by administering an effect amount of the peptide:
I-A-B-C-D-E-F-G-H-II (General Formula) wherein A is Ala, Gly, Val, Ser, Thr or absent, B is Ala, Gly, Val, Ser, Thr or absent, C is Ser, Thr or absent, D is Ser, Thr, Asn, Glu, Arg, IIe, Leu or absent, E is Ser, Thr,
Asp or absent, F is Thr, Ser, Asn, Glu, Lys, Trp or absent, G is tyr or absent; H is Thr, Arg, Gly, Met, Met(O), Gys, Thr, Gly or absent, I is Cys or absent, II is Cys, an amide group, substituted amide group, an ester group or absent.

L8 ANSWER 8 OF 46 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 2000-128304 [12] WPIDS
DNC C2000-039402
TI New vaccine for prevention of gram-negative **bacterial infections** and endotoxin related disorders, comprises complex of **peptide** and **LPS**.
DC B04 B05 D16
IN PORRO, M
PA (BIOS-N) BIOSYNTH SRL
CYC 26
PI EP 976402 A2 20000202 (200012)* EN 43p
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
CA 2279316 A1 20000129 (200028) EN
ADT EP 976402 A2 EP 1999-202476 19990727; CA 2279316 A1 CA 1999-2279316 19990729
PRAI US 1998-124280 19980729

AB EP 976402 A UPAB: 20000308
NOVELTY - A vaccine for preventing gram negative infections and the effects of endotoxins is new and comprises a complex obtained by combining
LPS free or in conjugate form with a sufficient amount of a peptide which is capable of producing a non-toxic, highly immunogenic complex.

DETAILED DESCRIPTION - A vaccine for preventing gram negative infections and the effects of endotoxins is new and comprises a complex obtained by combining LPS free or in conjugate form with a sufficient amount of a peptide which is capable of producing a non-toxic, highly immunogenic complex. The peptide is of the formula (a) - (c):
(a) (A)n;
(b) (AB)m; and/or
(c) (ABC)p.
A = a cationic amino acid e.g. Lysine or Arginine;
B = a hydrophobic amino acid e.g. Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan;
C = a hydrophobic amino acid e.g. Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan;
n = integer of 7-16;
m = integer of 4-20;
p = integer of 4-20.

An INDEPENDENT CLAIM is also included for a method for the preparation of a vaccine for prevention of gram-negative infections and the effects of endotoxins.

ACTIVITY - Antibacterial.
No relevant activity data given.

MECHANISM OF ACTION - The excess **peptide** significantly stabilizes the **LPS peptide** complex from the likely antagonistic activity of natural LPS-receptor proteins present on specialized cells of the immune system.

USE - The vaccine is useful for the prevention of **bacterial infections** caused by gram-negative bacteria and for the prevention of biological effects of homologous endotoxins, especially for preventing sepsis and septic shock.

ADVANTAGE - The toxic characteristic of LPS may be removed without eliminating the antigenic and immunogenic properties of LPS by binding the
LPS (via the lipid A moiety) to a peptide.
Dwg.0/0

L8 ANSWER 9 OF 46 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.DUPLICATE 1
AN 2000255567 EMBASE
TI A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases.
AU Vallespi M.G.; Glaria L.A.; Reyes O.; Garay H.E.; Ferrero J.; Arana M.J.
CS M.G. Vallespi, Division of Cellular Biology, Center for Biological Research, Calle 134 e/Ave. 25 y 23, Cubanacan, Havana, Cuba. maribel.guerra@cigb.edu.cu
SO Clinical and Diagnostic Laboratory Immunology, (2000) 7/4 (669-675).
Refs: 51
ISSN: 1071-412X CODEN: CDIMEN
CY United States
DT Journal; Article
FS 026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LA English
SL English
AB Previous studies have shown that cyclic peptides corresponding to residues
35 to 52 of the Limulus antilipopolysaccharide (anti-LPS) factor (LALF) bind and neutralize LPS-mediated in vitro and in vivo activities. Therapeutic approaches based on agents which bind and neutralize LPS

activities are particularly attractive because these substances directly block the primary stimulus for the entire proinflammatory cytokine cascade. Here we describe new activities of the LALF31-52 **peptide**, other than its **LPS** binding ability. Surprisingly, supernatants from human mononuclear cells stimulated with the LALF peptide are able to induce in vitro antiviral effects on the Hep-2 cell line mediated by gamma interferon (IFN-.gamma.) and IFN- .alpha.. Analysis of the effect of LALF31-52 on tumor necrosis factor (TNF) and nitric oxide (NO) production by LPS-stimulated peritoneal macrophages revealed that a pretreatment with the **peptide** decreased **LPS**-induced TNF production but did not affect NO generation. This indicates that the LALF **peptide** modifies the **LPS**-induced response. In a model in mice with peritoneal fulminating sepsis, LALF31-52 protected the mice when administered prophylactically, and this effect is related to reduced systemic TNF-.alpha. levels. This study demonstrates, for the first time, the anti-inflammatory properties of the LALF-derived peptide. These properties widen the spectrum of the therapeutic potential for this LALF-derived peptide and the molecules derived from it. These agents may be useful in the prophylaxis and therapy of viral and **bacterial infectious** diseases, as well as for septic shock.

L8 ANSWER 10 OF 46 USPATFULL
AN 1999:40567 USPATFULL
TI Porphenins--antibiotic peptides
IN Kokryakov, Vladimir N., Los Angeles, CA, United States
Harwig, Sylvia S.L., Woodland Hills, CA, United States
Lehrer, Robert I., Santa Monica, CA, United States
PA Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5889152 19990330
AI US 1995-477131 19950607 (8)
RLI Division of Ser. No. US 1994-222798, filed on 5 Apr 1994
DT Utility
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Lau, Kawai
LREP Morrison & Foerster
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptide-based compounds containing multiple proline residues are useful as preservatives and in preventing, treating, or ameliorating microbial **infection**, especially Gram-negative **bacterial infection** in animals and plants, in treating conditions characterized by the presence of LPS. These compounds are of the formula ##STR1## including the N-terminal acylated and/or C-terminal amidated or esterified forms thereof

wherein each of A.sub.1, A.sub.5, A.sub.10, A.sub.14 and A.sub.20 is independently Ala, Gly or Ser;

each of A.sub.2, A.sub.4, A.sub.7, A.sub.9, A.sub.11, A.sub.12, A.sub.13, A.sub.16, A.sub.17, A.sub.19 and A.sub.22 is independently a hydrophobic amino acid selected from the group consisting of Ile, Leu, Val, Phe and Met;

each of A.sub.3 and A.sub.8 is independently a neutral polar amino acid selected from Asn and Gln or is a hydrophobic amino acid selected from the group consisting of Ile, Leu, Val, Phe and Met;

each of A.sub.6, A.sub.18 and A.sub.21 is independently a basic amino

acid selected from Arg, Lys, and Har; and

wherein A.sub.15 is Trp or a basic amino acid selected from Lys, Arg and Har;

wherein n is an integer of 1-6; and

the antimicrobial or LPS-binding fragments thereof. Recombinant materials for the production of these peptides are also disclosed.

L8 ANSWER 11 OF 46 USPATFULL
AN 1999:27732 USPATFULL
TI Antimicrobial cationic peptides
IN Hancock, Robert E. W., Vancouver, Canada
Karunaratne, Nedra, Vancouver, Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 5877274 19990302
AI US 1995-460464 19950602 (8)
DT Utility
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Longton, Enrique D.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 1008
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH.sub.2 -KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO:1) and NH.sub.2 -KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO:2).

L8 ANSWER 12 OF 46 USPATFULL
AN 1999:27610 USPATFULL
TI Method for inhibiting production of tumor necrosis factor
IN Pereira, Heloise Anne, Edmond, OK, United States
PA The Board of Regents of the University of Oklahoma, United States (U.S. corporation)
PI US 5877151 19990302
AI US 1997-840519 19970421 (8)
RLI Continuation of Ser. No. US 1995-482328, filed on 7 Jun 1995, now patented, Pat. No. US 5627262, issued on 6 May 1997 which is a continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916, issued on 4 Mar 1997 which is a continuation-in-part of Ser. No. US 1992-939931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874, issued on 17 Oct 1995 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885, issued on 16 Jan 1996 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.
LREP Dunlap & Codding, P.C.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 804
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention contemplates a composition and method for treating septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective

amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use
may comprise a peptide comprising amino acids 20-44 or 120-146 of CAP37 or subunits thereof.

L8 ANSWER 13 OF 46 USPATFULL
AN 1999:4632 USPATFULL
TI Anti-fungal peptides
IN Little, II, Roger G., Benicia, CA, United States
Lim, Edward, Walnut Creek, CA, United States
Fadem, Mitchell B., Carmel Valley, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5858974 19990112
AI US 1996-621259 19960321 (8)
RLI Continuation-in-part of Ser. No. US 1995-504841, filed on 20 Jul 1995
DT Utility
EXNAM Primary Examiner: Davenport, Avis M.
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 5315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino aids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides.

L8 ANSWER 14 OF 46 USPATFULL
AN 1999:1767 USPATFULL
TI Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
IN Little, II, Roger G., Benicia, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5856438 19990105
AI US 1995-485445 19950607 (8)
RLI Continuation of Ser. No. US 1994-306473, filed on 15 Sep 1994, now patented, Pat. No. US 5652332 And a continuation-in-part of Ser. No. US 1994-273540, filed on 11 Jul 1994, now abandoned And Ser. No. US 1994-274299, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-209762, filed on 11 Mar 1994, now patented, Pat. No. US 5696085 which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned , said Ser.
No. US 306473 which is a continuation-in-part of Ser. No. US 209762 , said Ser. No. US 183222 which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility
EXNAM Primary Examiner: Davenport, Avis M.
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 94 Drawing Figure(s); 78 Drawing Page(s)
LN.CNT 5756
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and
variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal

activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.

L8 ANSWER 15 OF 46 JAPIO COPYRIGHT 2000 JPO
AN 1999-335396 JAPIO
TI NEW ANTIMICROBIAL PEPTIDE
IN HIRATA RIKUMASA
PA SEIKAGAKU KOGYO CO LTD
PI JP 11335396 A 19991207 Heisei
AI JP1998-176466 (JP10176466 Heisei) 19980623
PRAI JP 1998-78136 19980325
SO PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 99
AB PROBLEM TO BE SOLVED: To obtain a new antimicrobial peptide consisting of a human-derived peptide having a specific amino acid sequence, having lipopolysaccharide(LPS) binding activity, excellent in antimicrobial activity and LPS-neutralizing activity, and useful as an antimicrobial agent, endotoxin removing agent or the like.
SOLUTION: This new peptide is such one as to contain at least an amino acid sequence of the formula and have lipopolysaccharide(LPS) binding activity, antimicrobial activity and LPS-neutralizing activity, being useful as an antimicrobial agent, therapeutic agent for **bacterial infectious** diseases, endotoxin shock inhibitor, endotoxin removing agent or the like. This new peptide is obtained by designing an amino acid
sequence constructing a **peptide** with antimicrobial activity, **LPS** binding activity and LPS-neutralizing activity raised through the change in the balance between the hydrophilic portion and hydrophobic portion as a result of substituting the amino acid residue at a specific site on a partial **peptide** of the **LPS**-bound domain of human-derived CAP18 by another specific amino acid residue, and by chemically synthesizing the above peptide with peptide solid phase synthesis or the like.
COPYRIGHT: (C)1999,JPO

L8 ANSWER 16 OF 46 CAPLUS COPYRIGHT 2000 ACS
AN 2000:15169 CAPLUS
DN 132:333324
TI "Designer" peptides derived from bactericidal/permeability-increasing protein recapitulate its endotoxin binding region
AU Weiss, Carl A., III; Wasiluk, Karen R.; Kellogg, Todd A.; Gray, Beulah H.;
Mayo, Kevin H.; Dunn, David L.
CS Department of Surgery, University of Minnesota, Minneapolis, MN, USA
SO Surg. Forum (1999), 50, 217-219
CODEN: SUFOAX; ISSN: 0071-8041
PB American College of Surgeons
DT Journal
LA English
AB A synthetic 27-amino acid peptide of bactericidal/permeability-increasing protein is bactericidal toward Pseudomonas aeruginosa and abrogates LPS-induced TNF-.alpha. release from macrophages in vitro, but this activity diminishes in vivo. We hypothesized that BPI-derived peptides designed to recapitulate the native secondary structure of the active domain (amphipathic .beta.-turn) would exhibit more potent anti-LPS activity than unmodified peptides during murine endotoxemia and would be useful adjunctive reagents for the treatment of serious gram-neg. **bacterial infection** and sepsis. The results show that modified BPI-derived **peptide** inhibited **LPS**-induced TNF-.alpha. and is a promising agent in treatment of gram-neg. **bacterial infection** and sepsis.
RE.CNT 13
RE
(1) Abello, P; Free Radicals in Diagnostic Medicine 1994, P253 CAPLUS
(2) Appelmelk, B; Infect Immun 1994, V62, P3564 CAPLUS
(4) Beamer, L; Science V276, P1861 CAPLUS

(6) Dentener, M; J Immunol 1993, V151, P4258 CAPLUS
(7) Fenton, M; J Leukocyte Biol 1998, V64, P25 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 46 USPATFULL
AN 1998:135009 USPATFULL
TI Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
IN Gray, Beulah H., St. Paul, MN, United States
Haseman, Judith R., Eagan, MN, United States
Mayo, Kevin H., Minnetonka, MN, United States
PA Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)
PI US 5830860 19981103
AI US 1996-653632 19960524 (8)
RLI Continuation-in-part of Ser. No. US 1994-218026, filed on 24 Mar 1994
DT Utility
EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Merchant, Gould, Smith, Edell & Welter
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 3162
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides biologically active peptides derived from or corresponding to regions of a bactericidal permeability increasing factor (B/PI). The peptides are preferably about 10 to 100 amino acids long and have bactericidal and/or endotoxin neutralizing activity. The peptides can be prepared by automated protein synthesis or by recombinant DNA methods. The peptides are useful in methods to treat and prevent **bacterial infection** in the body and on surfaces. The peptides are also useful to treat endotoxin shock and have endotoxin neutralizing activity.

L8 ANSWER 18 OF 46 USPATFULL
AN 1998:108385 USPATFULL
TI Prophenins - antibiotic peptides
IN Kokryakov, Vladimir N., Los Angeles, CA, United States
Harwig, Sylvia S. L., Woodland Hills, CA, United States
Lehrer, Robert I., Santa Monica, CA, United States
PA University of California, Los Angeles, CA, United States (U.S. corporation)
PI US 5804553 19980908
AI US 1994-222798 19940405 (8)
DT Utility
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Lau, Kawai
LREP Morrison & Foerster LLP
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1008
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptide-based compounds containing multiple proline residues are useful as preservatives and in preventing, treating, or ameliorating microbial **infection**, especially Gram-negative **bacterial infection** in animals and plants, in treating conditions characterized by the presence of LPS. These compounds are of the formula ##STR1## including the N-terminal acylated and/or C-terminal amidated or esterified forms thereof

wherein each of A.sub.1, A.sub.5, A.sub.10, A.sub.14 and A.sub.20 is

independently Ala, Gly or Ser;

each of A.sub.2, A.sub.4, A.sub.7, A.sub.9, A.sub.11, A.sub.12, A.sub.13, A.sub.16, A.sub.17, A.sub.19 and A.sub.22 is independently a hydrophobic amino acid selected from the group consisting of Ile, Leu, Val, Phe and Met;

each of A.sub.3 and A.sub.8 is independently a neutral polar amino acid selected from Asn and Gln or is a hydrophobic amino acid selected from the group consisting of Ile, Leu, Val, Phe and Met;

each of A.sub.6, A.sub.18 and A.sub.21 is independently a basic amino acid selected from Arg, Lys, and Har; and

wherein A.sub.15 is Trp or a basic amino acid selected from Lys, Arg and
Har;

wherein n is an integer of 1-6; and

the antimicrobial or LPS-binding fragments thereof. Recombinant materials for the production of these peptides are also disclosed.

L8 ANSWER 19 OF 46 USPATFULL
AN 1998:92001 USPATFULL
TI Treatment of endotoxin-associated disorders with cationic peptides
IN Hancock, Robert E. W., Vancouver, Canada
Piers, Kevin L., Richmond, Canada
Brown, Melissa H., Vancouver, Canada
Kelly, Niamh, Vancouver, Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 5789377 19980804
AI US 1995-405234 19950313 (8)
RLI Continuation-in-part of Ser. No. US 1993-110502, filed on 20 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-933492, filed on 21 Aug 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Fish & Richardson, P.C.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 24 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 1454
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the microbial production of a cationic peptide having anti-microbial activity is provided, wherein the cationic peptide is first produced as a fusion protein having an anionic portion for suppressing the antimicrobial activity of the cationic portion. A novel cationic **peptide** having anti-microbial activity and **LPS**-binding activity is also provided. Such peptides are useful for suppressing the growth of bacteria and for the treatment of endotoxemia-associated disorders.

L8 ANSWER 20 OF 46 USPATFULL
AN 1998:88809 USPATFULL
TI Synthetic peptides with bactericidal activity and endotoxin neutralizing
activity for gram negative bacteria and methods for their use
IN Gray, Beulah, St. Paul, MN, United States
Haseman, Judith R., Eagan, MN, United States
Mayo, Kevin, Minnetonka, MN, United States
PA Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)
PI US 5786324 19980728

AI US 1994-218026 19940324 (8)
DT Utility
EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 2603
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides biologically active peptides derived from or corresponding to regions of a bactericidal permeability increasing factor (B/PI). The peptides are about 10 to 100 amino acids long and have bactericidal and/or endotoxin neutralizing activity. The peptides can be prepared by automated DNA synthesis or by recombinant DNA methods. The peptides are useful in methods to treat and prevent **bacterial infection** in the body and on surfaces. The peptides are also useful to treat endotoxin shock.

L8 ANSWER 21 OF 46 USPATFULL
AN 1998:65346 USPATFULL
TI Biologically active peptides from funcional domains of bactericidal/permeability-increasing protein and uses thereof
IN Little, Roger G., Benicia, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5763567 19980609
AI US 1995-473344 19950607 (8)
RLI Continuation of Ser. No. US 1994-209762, filed on 11 Mar 1994 which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility
EXNAM Primary Examiner: Carlson, Karen C.
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 86 Drawing Figure(s); 70 Drawing Page(s)
LN.CNT 3868
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.

L8 ANSWER 22 OF 46 USPATFULL
AN 1998:57873 USPATFULL
TI Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
IN Andersen, Anders Jorgen, Kokkedal, Denmark
Aston, Roger, Wiltshire, England
Carlen, Peter Louis, Ontario, Canada
Doob, Penelope Reed, Ontario, Canada
MacFadden, Douglas Kevin, Ontario, Canada
Phipps, David James, Ontario, Canada
Rathjen, Deborah, New South Wales, Australia
Widmer, Fred, New South Wales, Australia
PA Peptide Technology Limited, Dee Why, Australia (non-U.S. corporation)

Drug Royalty Corporation, New South Wales, Australia (non-U.S. corporation)
PI US 5756449 19980526
WO 9320102 19931014
AI US 1995-302829 19950224 (8)
WO 1993-GB649 19930329
19950224 PCT 371 date
19950224 PCT 102(e) date
PRAI DK 1992-645 19920514
DT Utility
EXNAM Primary Examiner: Cain, Edward J.
LREP Banner & Witcoff, Ltd.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2365
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating inflammatory bowel disease in patients in need of such treatment by administering an effective amount of: I-A-B-C-D-E-F-G-H-II (General Formula I), wherein A is Ala, Gly, Val, Ser, Thr or absent, B is Ala, Gly, Val, Ser, Thr, or absent, C is Ser, Thr or absent. D is Ser, Thr, Asn, Glu, Arg, IIe, Leu or absent, E is Ser, Thr, Asp or absent, F is Ser, Thr, Asp or absent, G is Tyr or absent, H is Thr, Arg, Gly, Met, Met(O), Cys, Thr, Gly or absent, and I is Cys or absent II is Cys, an amide group, substituted amid group, an ester group or absent. At least one of the amino acids optionally being substituted by a monomeric or polymeric carbohydrate or derivative thereof, such substitution being accomplished through hydroxyl and/or amino and/or amido groups of the amino acids, and wherein the peptide comprises at least 4 amino acid residues, and a pharmaceutically acceptable salt thereof.

L8 ANSWER 23 OF 46 USPATFULL
AN 1998:36361 USPATFULL
TI Alteration of immune response using pan DR-binding peptides
IN Sette, Alessandro, La Jolla, CA, United States
Gaeta, Federico, Foster City, CA, United States
Grey, Howard M., La Jolla, CA, United States
Sidney, John, La Jolla, CA, United States
Alexander, Jeffrey L., Encinita, CA, United States
PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5736142 19980407
AI US 1994-305871 19940914 (8)
RLI Continuation-in-part of Ser. No. US 1993-121101, filed on 14 Sep 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Cunningham, Thomas M.
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 2085
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions and methods of inhibiting or inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus. These peptides are referred to as pan DR binding peptides. The pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft

rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.

L8 ANSWER 24 OF 46 USPATFULL
AN 1998:33895 USPATFULL
TI Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
IN Little, Roger G., Benicia, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5733872 19980331
AI US 1994-209762 19940311 (8)
RLI Continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility
EXNAM Primary Examiner: Carlson, Karen C.
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 86 Drawing Figure(s); 70 Drawing Page(s)
LN.CNT 3967
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.

L8 ANSWER 25 OF 46 USPATFULL
AN 1998:25345 USPATFULL
TI Immuno-potentiating systems for preparation of immunogenic materials
IN Lowell, George H., 6303 Westlin Run Dr., Baltimore, MD, United States 21215
PI US 5726292 19980310
AI US 1993-143365 19931029 (8)
RLI Continuation-in-part of Ser. No. US 1993-29666, filed on 11 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1989-336952, filed on 12 Apr 1989, now abandoned And a continuation-in-part of Ser. No. US 1991-642093, filed on 16 Jan 1991, now abandoned which is a continuation of Ser. No. US 1987-65440, filed on 23 Jun 1987, now abandoned
DT Utility
EXNAM Primary Examiner: Budens, Robert D.
LREP Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1228
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to improved immunopotentiating systems for preparation of immunogenic materials. More particularly, the invention is directed to immunogenic compositions containing a protein, polypeptide, or peptide, a hydrophobic anchor, and a proteosome. The immunogenic compositions are suitable for use as therapeutic agents and vaccines.

L8 ANSWER 26 OF 46 USPATFULL
AN 1998:1683 USPATFULL

TI Methods for identifying inhibitors of LPS-mediated LBP binding
IN Mintz, Douglas N., New York, NY, United States
Tobias, Peter, San Diego, CA, United States
Ulevitch, Richard, Del Mar, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 5705398 19980106
AI US 1994-205719 19940302 (8)
DT Utility
EXNAM Primary Examiner: Allen, Marianne P.; Assistant Examiner: Duffy, Patricia A.
LREP Fitting, Thomas; Holmes, Emily
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1313
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes a rapid method for the identification of
compounds/reagents which inhibit lipopolysaccharide (LPS) binding to LPS
binding protein (LBP), and kits for practicing the method.

L8 ANSWER 27 OF 46 USPATFULL
AN 97:107054 USPATFULL
TI Treatment of endotoxin-associated disorders with cationic peptides
IN Hancock, Robert E. W., Vancouver, Canada
Piers, Kevin L., Red Deer, Canada
Brown, Melissa H., Canterbury, Australia
Kelly, Niamh, Vancouver, Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 5688767 19971118
AI US 1996-614516 19960313 (8)
RLI Division of Ser. No. US 1995-405234, filed on 13 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-110502, filed on 20 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-933492, filed on 21 Aug 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Patterson, Jr, Charles L.
LREP Fish & Richardson, P.C.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 1709
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the microbial production of a cationic peptide having anti-microbial activity is provided, wherein the cationic peptide is first produced as a fusion protein having an anionic portion for suppressing the antimicrobial activity of the cationic portion. A novel cationic **peptide** having anti-microbial activity and **LPS**-binding activity is also provided. Such peptides are useful for suppressing the growth of bacteria and for the treatment of endotoxemia-associated disorders.

L8 ANSWER 28 OF 46 USPATFULL
AN 97:66218 USPATFULL
TI Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
IN Little, II, Roger G., Benicia, CA, United States
PA XOMA, Berkeley, CA, United States (U.S. corporation)
PI US 5652332 19970729
AI US 1994-306473 19940915 (8)
RLI Continuation-in-part of Ser. No. US 1994-209762, filed on 11 Mar 1994 which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14

Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility
EXNAM Primary Examiner: Schain, Howard E.; Assistant Examiner: Davenport, A. M.
LREP Banner & Allegretti, Ltd.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 94 Drawing Figure(s); 78 Drawing Page(s)
LN.CNT 4247
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and
variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.

L8 ANSWER 29 OF 46 USPATFULL
AN 97:63993 USPATFULL
TI Method and composition for the treatment of septic shock
IN Pereira, Heloise Anne, Oklahoma City, OK, United States
Brackett, Daniel J., Seminole, OK, United States
Lerner, Megan R., Shawnee, OK, United States
PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)
PI US 5650392 19970722
AI US 1995-455485 19950531 (8)
RLI Division of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented,
Pat. No. US 5607916 which is a continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484855 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is
a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Harle, Jennifer
LREP Dunlap & Codding, P.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 608
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention contemplates a composition and method for treating
septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective
amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use
may comprise a peptide comprising amino acids 20-44 of CAP37 or a subunit thereof.

L8 ANSWER 30 OF 46 USPATFULL
AN 97:38605 USPATFULL

TI Method and composition for the treatment of septic shock
IN Pereira, Heloise A., Edmond, OK, United States
PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)
PI US 5627262 19970506
AI US 1995-482328 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916, issued on 4 Mar 1997 which is a continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874, issued on 17 Oct 1995 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885, issued on 16 Jan 1996 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.
LREP Dunlap & Codding, P.C.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention contemplates a composition and method for treating septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 or 120-146 of CAP37 or subunits thereof.

L8 ANSWER 31 OF 46 USPATFULL
AN 97:29335 USPATFULL
TI Methods and compositions for detecting lipopolysaccharides using CAP18 fragments
IN Larrick, James W., Woodside, CA, United States
Wright, Susan C., Saratoga, CA, United States
PA Panorama Research, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5618675 19970408
AI US 1994-313681 19940927 (8)
RLI Continuation-in-part of Ser. No. US 1992-916961, filed on 16 Jul 1992, now patented, Pat. No. US 5277707 And Ser. No. US 1992-916765, filed on 17 Jul 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Portner, Ginny Allen
LREP Townsend & Townsend & Crew LLP
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 1963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the treatment and diagnosis of lipopolysaccharide-related conditions and coagulant-related disease are provided. Compositions include polypeptides which are identical or homologous to a certain cationic protein (CAP18) obtained from mammalian granulocytes, particularly including a reactive nitrogen inhibiting peptide (RNIP) fragment found at the carboxyl-terminus of CAP18. Polypeptides are capable of binding to LPS and inhibiting LPS-mediated activation of macrophage, as well as interfering with the clotting

cascade to inhibit coagulation in conditions such as disseminated intravascular coagulation. Compositions comprising the polypeptides in a suitable pharmaceutical carrier are also provided.

L8 ANSWER 32 OF 46 USPATFULL
AN 97:18141 USPATFULL
TI Method and composition for the treatment of septic shock
IN Pereira, Heloise A., Oklahoma City, OK, United States
Brackett, Daniel J., Seminole, OK, United States
Lerner, Megan R., Shawnee, OK, United States
PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)
PI US 5607916 19970304
AI US 1994-235399 19940429 (8)
RLI Continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874, issued on 17 Oct 1995 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885, issued on 16 Jan 1996 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.
LREP Dunlap & Codding, P.C.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 643
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention contemplates a composition and method for treating septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 of CAP37 or a subunit thereof.

L8 ANSWER 33 OF 46 USPATFULL
AN 96:120869 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN Porro, Massimo, Siena, Italy
PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)
PI US 5589459 19961231
AI US 1994-280397 19940726 (8)
RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Davenport, Avis M.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid

residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.

L8 ANSWER 34 OF 46 USPATFULL
AN 96:82450 USPATFULL
TI Methods and vaccines comprising surface-active copolymers
IN Hunter, Robert L., Tucker, GA, United States
PA Emory University, Atlanta, GA, United States (U.S. corporation)
PI US 5554372 19960910
AI US 1995-420333 19950411 (8)
RLI Continuation of Ser. No. US 1993-133760, filed on 7 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-716807, filed on 21 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-544831, filed on 27 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-449086, filed on 8 Dec 1989, now abandoned which is a continuation of Ser. No. US 1989-341315, filed on 21 Apr 1989, now abandoned which is a continuation of Ser. No. US 1988-208335, filed on 17 Jun 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-75187, filed on 16 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-909964, filed on 22 Sep 1986, now abandoned
DT Utility
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Shaver, Jennifer
LREP Jones & Askew
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 24 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 2669
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention comprises adjuvants which, when admixed with an antigen and administered into a human or animal, will induce a more intense immune response to the antigen than when the antigen is administered alone. In many cases, the adjuvant that is described as the present invention will increase overall titer of antibodies of a specific isotype which are specific for the antigen. For example, in mice, when the adjuvant of the present invention is admixed with a conventional antigen, the isotype that is induced in the mouse is changed from a predominantly IgG1 isotype to the more protective IgG2 isotype and, in some cases, IgG3 isotype. Thus, by practicing the present invention, one can improve the overall protective effect of conventional vaccines.

L8 ANSWER 35 OF 46 USPATFULL
AN 96:34020 USPATFULL
TI Method for using polymyxin-coated substrate for lipopolysaccharide detection
IN Blais, Burton W., 78 Welsh Private Road, Ottawa, Ontario, Canada K1G 4Y1
Yamazaki, Hiroshi, 22 Alderbrook Drive, Nepean, Ontario, Canada K2H 5W5
PI US 5510242 19960423
AI US 1993-87013 19930707 (8)
RLI Continuation of Ser. No. US 1991-697683, filed on 9 May 1991, now abandoned
PRAI CA 1990-2017093 19900518
CA 1991-2037726 19910307
CA 1991-2037727 19910307
DT Utility

EXNAM Primary Examiner: Walsh, Stephen G.; Assistant Examiner: Kemmerer, Elizabeth C.
LREP Nixon & Vanderhye
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved device is provided which may be used, e.g. for immunoassay of lipopolysaccharides or for removing LPS pyrogens from aqueous solutions, or for removing LPS endotoxins from wounds. Such device comprises, in combination, a substrate, e.g. plastic, i.e. polystyrene, polycarbonate, polymethylmethacrylate or polyvinyl chloride, or a woven cloth, i.e. a rayon/polyester cloth or a polyester cloth, or a non-woven cloth, i.e. a rayon/polyester cloth, or a polyester cloth, or paper, which is adapted to receive a sample to be tested, and an oligopeptide, or a hydrophobic polypeptide or a polymyxin, e.g. polymyxin B, polymyxin B.sub.1, polymyxin B.sub.2, polymyxin D.sub.1, polymyxin D.sub.2, or polymyxin E, adhered to the substrate.

L8 ANSWER 36 OF 46 USPATFULL
AN 96:29533 USPATFULL
TI Muramyl compounds for treatment of septic shock
IN Aston, Roger, Malmesbury, United Kingdom
PA Peptech (UK) Limited, England (non-U.S. corporation)
PI US 5506204 19960409
WO 9310148 19930527
AI US 1994-244154 19940518 (8)
WO 1992-GB2137 19921119
19940518 PCT 371 date
19940518 PCT 102(e) date
PRAI GB 1991-24500 19911119
GB 1992-10013 19920508
DT Utility
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Prickril, Benet
LREP Banner & Allegretti, Ltd.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 931
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Muramyl peptide compounds which: (a) are non-pyrogenic; and/or (b) ameliorate endotoxin-induced weight loss and/or hypophagia; and/or (c) reduce TNF production; and/or (d) stimulate macrophage to produce endotoxin are useful, in the treatment of septic shock, cachexia and other life-threatening inflammatory conditions. Preferred compounds include N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine (GMDP) and N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-glutamic acid (GMDP-A).

L8 ANSWER 37 OF 46 USPATFULL
AN 96:5884 USPATFULL
TI Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
IN Pereira, Heloise A., Decatur, GA, United States
Spitznagel, John K., Decatur, GA, United States
PA Emory University, Atlanta, GA, United States (U.S. corporation)
PI US 5484885 19960116
AI US 1992-855417 19920319 (7)
RLI Continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US

1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Furman, Keith C.
LREP Needle & Rosenberg
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 2498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants of monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.

L8 ANSWER 38 OF 46 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
DUPLICATE
2
AN 1995-098719 [13] WPIDS
DNN N1995-077922 DNC C1995-044944
TI New lipo polysaccharide binding and neutralising peptide(s) - used for treating or preventing LPS associated conditions or for detecting or removing bacterial LPS..
DC B04 C03 D16 S03
IN HOESS, A; LIDDINGTON, R C
PA (MORP-N) MORPHOSYS AG; (MORP-N) MORPHOSYS GES PROTEINOPTIMIERUNG MBH
CYC 20
PI WO 9505393 A2 19950223 (199513)* EN 45p
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: CA JP US
EP 664814 A1 19950802 (199535) EN
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
WO 9505393 A3 19950323 (199613)
JP 08503490 W 19960416 (199645) 56p
ADT WO 9505393 A2 WO 1994-EP2747 19940818; EP 664814 A1 EP 1994-926848 19940818, WO 1994-EP2747 19940818; WO 9505393 A3 WO 1994-EP2747 19940818; JP 08503490 W WO 1994-EP2747 19940818, JP 1995-506764 19940818
FDT EP 664814 A1 Based on WO 9505393; JP 08503490 W Based on WO 9505393
PRAI US 1993-111625 19930825; US 1993-108415 19930818
AB WO 9505393 A UPAB: 19990424
(A) A lipopolysaccharide (**LPS**) - binding **peptide** is claimed comprising a **LPS** binding domain comprising at least (a) the amino acid sequence A1-A2-A3-A4-A5-A6-A7-A8 (I), in which A1 = a polar or positively charged amino acid, pref. C, H, K, N, Q, R, S, T, W or Y; A2 = a hydrophobic amino acid, pref. A, F, H, I, L, M, V or W; A3 = a basic amino acid, pref. H, K or R; A4 = a hydrophobic or positively charged amino acid, pref. A, F, H, I, K, L, M, R, V or W; A5 = a hydrophobic, polar or positively charged amino acid, pref. A, C, F, H, I, K, L, M, N, Q, R, S, T, V, W or Y; A6 = a positively charged amino acid, pref. K or R; A7 = as for A5; A8 = as for A4; (b) a corresp. inverse amino acid sequence; or (c) a variation of the amino acid sequence (a) or (b) capable of effectively binding to LPS. Also claimed are: (B) a DNA sequence encoding a peptide as in (A); (C) a recombinant vector contg. a DNA

sequence as in (B); (D) a microorganism contg. a recombinant vector as in (C) (E) a diagnostic kit contg. an **LPS**-binding **peptide** as in (A) or a set of such peptides.

USE - The peptides can be used for treating Gram-negative or Gram-positive sepsis, **bacterial** or fungal **infections** or heparin-mediated anti-coagulation (claimed). They can also be used for inhibition of angiogenesis, tumour cell proliferation or endothelial cell proliferation (claimed). They can also be used for diagnosis, e.g. of septic conditions (claimed). They can also be immobilised and used for removing LPS or bacteria from solns. (claimed).

ADVANTAGE - The peptides effectively bind to LPS and interact specifically with LPS with an association constant > 105 M-1. The peptides also show bactericidal and heparin binding activity.

Dwg.0/15

L8 ANSWER 39 OF 46 USPATFULL
AN 95:92525 USPATFULL
TI Method of increasing monocyte chemotaxis with CAP37 and monocyte chemotactic portions thereof
IN Pereira, Heloise A., Decatur, GA, United States
Spitznagel, John K., Decatur, GA, United States
PA Emory University, Atlanta, GA, United States (U.S. corporation)
PI US 5458874 19951017
AI US 1992-969931 19921030 (7)
RLI Continuation of Ser. No. US 1992-855417, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Furman, Keith C.
LREP Needle & Rosenberg
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 2618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.

L8 ANSWER 40 OF 46 USPATFULL
AN 94:106884 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN Porro, Massimo, Siena, Italy
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5371186 19941206
AI US 1992-819893 19920116 (7)
DCD 20111025
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.

LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel peptides of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the prevention and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L8 ANSWER 41 OF 46 USPATFULL
AN 94:93312 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN Porro, Massimo, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5358933 19941025
AI US 1993-49871 19930419 (8)
RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel peptides are disclosed which are based on the formula:

R.sub.1 (Lys-Phe-Leu).sub.n --R

wherein n is an integer of from 1-10 and R and R.sub.1 are H or an amino acid residue or a fatty acid residue which are useful in the treatment of septic shock.

L8 ANSWER 42 OF 46 USPATFULL
AN 93:14545 USPATFULL
TI Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
IN Cowan, Jr., Fred M., 21 Shady Brook Dr., Colora, MD, United States 21917
PI US 5189014 19930223
AI US 1991-711709 19910607 (7)
RLI Continuation of Ser. No. US 1989-424088, filed on 19 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1986-911341, filed on 25 Sep 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-728142, filed on 26 Apr 1985, now abandoned which is a continuation of Ser. No. US 1980-204945, filed on 7 Nov 1980, now abandoned which is a continuation-in-part of Ser. No. US 1979-99741, filed on 3 Dec 1979, now abandoned
DT Utility
EXNAM Primary Examiner: Waddell, Frederick E.; Assistant Examiner: Hook, Gregory
LREP Field, Milton M.

CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1756
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of immunotherapy for treating diseases and disorders which involve cellular Fc receptor mediated immune responses in humans and animals is disclosed. Abnormal or undesirable cellular Fc receptor mediated immune reactions are beneficially altered by locally or systemically administering an exogenous Fc receptor polypeptide, in particular a multivalent protein having in its molecule several Fc receptor sites, such as staphylococcus protein A, or monovalent Fc receptor possessing only a single Fc receptor site.

L8 ANSWER 43 OF 46 CAPLUS COPYRIGHT 2000 ACS
AN 1993:574194 CAPLUS
DN 119:174194
TI Muramyl peptide compounds for treatment of septic shock
IN Aston, Roger
PA Biokine Technology Ltd., UK
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9310148	A1	19930527	WO 1992-GB2137	19921119
	W: AU, BG, BR, CA, CS, FI, HU, JP, KR, NO, PL, RO, RU, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	AU 9229492	A1	19930615	AU 1992-29492	19921119
	AU 666890	B2	19960229		
	ZA 9208958	A	19940519	ZA 1992-8958	19921119
	EP 615522	A1	19940921	EP 1992-923873	19921119
	EP 615522	B1	19990922		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	JP 07508497	T2	19950921	JP 1992-509106	19921119
	RU 2139086	C1	19991010	RU 1994-27574	19921119
	AT 184883	E	19991015	AT 1992-923873	19921119
	US 5506204	A	19960409	US 1994-244154	19940518
PRAI	GB 1991-24500	19911119			
	GB 1992-10013	19920508			
	WO 1992-GB2137	19921119			

OS MARPAT 119:174194
AB Muramyl peptide compds. which (1) are nonpyrogenic; and/or (2) ameliorate endotoxin-induced wt. loss and/or hypophagia; and/or (3) reduce TNF prodn.; and/or (4) stimulate macrophages to process endotoxin are useful in the treatment of septic shock, cachexia, and other life-threatening inflammatory conditions. Preferred compds. include N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine (I) and N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-glutamic acid. Thus, in patients undergoing surgery for colon cancer, treatment with I reduced the incidence of septic complications from 50 to 18.75%. Importantly and more specifically, the redn. in mortality from 15 to 6.25% gives an indication of the effectiveness of the invention in treating or preventing septic shock, which is frequently the cause of death in such mortalities. Neutrophil function was maintained in the I-treated patients.

L8 ANSWER 44 OF 46 USPATFULL
AN 92:12734 USPATFULL
TI Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
IN Marra, Marian N., San Mateo, CA, United States

Scott, Randal W., Sunnyvale, CA, United States
PA INCYTE Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5089274 19920218
AI US 1990-468696 19900122 (7)
RLI Continuation-in-part of Ser. No. US 1989-310842, filed on 14 Feb 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Witz, Jean C.
LREP White, John P.
CLMN Number of Claims: 25
ECL Exemplary Claim: 4
DRWN 20 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1117
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method of inhibiting lipopolysaccharide (LPS)-mediated stimulation of cells. This method comprises contacting the cells, in the presence of a cell-stimulating amount of lipopolysaccharide, with Bactericidal/Permeability Increasing Protein (BPI) in an amount effective to inhibit cell stimulation.

L8 ANSWER 45 OF 46 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1990:109561 BIOSIS
DN BA89:59052
TI LIPOPOLYSACCHARIDE MODULATES CHEMOTACTIC PEPTIDE-INDUCED ACTIN POLYMERIZATION IN NEUTROPHILS.
AU HOWARD T H; WANG D; BERKOW R L
CS DEP. PEDIATR., DIV. HEMATOL.-ONCOL., CHILD. HOSP. ALA., 1600 7TH AVE. SOUTH, BIRMINGHAM, ALA. 35223.
SO J LEUKOCYTE BIOL, (1990) 47 (1), 13-24.
CODEN: JLBIE7. ISSN: 0741-5400.
FS BA; OLD
LA English
AB To study the effect of endotoxin (**LPS**) on the basal and chemotactic **peptide**, formyl-methionyl-leucyl-phenylalanine (fMLP)-induced alterations in neutrophil cytoskeleton, we purified (> 98%) LPS-free neutrophils (LPS- < 10 pg/ml LPS), compared their cytoskeletal organization to that of circulating neutrophils, and examined the effect of LPS exposure on the basal and fMLP-induced change in the cytoskeleton as reflected by F-actin content and distribution. Shape, F-actin content and distribution were monitored by FACS analysis and fluorescence microscopy of NBDphallicidin-stained cells. The F-actin content of basal and fMLP-activated, purified LPS- cells is similar to that of circulating neutrophils (defined as cells drawn in LPS- buffers at 37.degree. C and analyzed after < 10 seconds of ex vivo manipulation). LPS- cells are round with a diffuse F-actin distribution. Exposure of LPS- cells to LPS causes cell polarization and F-actin redistribution without net gain in F-actin content. **Peptide** activation of the **LPS**- cell causes actin polymerization, which is preceded by a brief lag time. Exposure of LPS- cells to LPS (LPS+) enhances fMLP-induced actin polymerization by: 1) increasing the maximal extent of polymerization; 2) shortening the lag time preceding polymerization and increasing the rate of polymerization; and 3) lowering fMLP dose required for half maximal F-actin response. The enhancement depends on LPS dose, duration of exposure, and temperature. To examine the mechanism whereby LPS enhances fMLP-induced actin polymerization, we determined the predominant end for filament growth in LPS- and LPS+ cells, the number of actin nuclei generated in LPS- and LPS+ by fMLP activation, and the number and affinity of fMLP receptors on LPS-

and LPS+ cells by 3[H]fMLP binding. Actin polymerization in both LPS- and LPS+ occurs predominantly by monomer addition to the barbed ends of nuclei, and the number of actin nuclei in basal and fMLP-activated LPS- and LPS+ cells is similar. LPS+ cells express three times more fMLP receptors than LPS- cells. The results show that LPS- cells are similar in cytoskeletal organization to circulating neutrophils, LPS causes shape change without change in F-actin content, and LPS enhances fMLP-induced actin polymerization response in neutrophils. The results suggest that LPS enhancement of actin polymerization response is associated with an increase in the number of fMLP receptors expressed on the cell surface.

L8 ANSWER 46 OF 46 MEDLINE
AN 88214962 MEDLINE
DN 88214962
TI Immunosuppressive effects of a trauma-induced suppressor active peptide.
AU Ozkan A N; Hoyt D B; Tompkins S; Ninnemann J L; Sullivan J J
CS Department of Surgery, University of California San Diego, School of Medicine.
NC GM-34007 (NIGMS)
SO JOURNAL OF TRAUMA, (1988 May) 28 (5) 589-92.
Journal code: KAF. ISSN: 0022-5282.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198808
AB The isolation and partial characterization of an immunosuppressive glycopeptide from sera of severely burned patients has previously been reported. Recently, a monoclonal antibody to this factor and an enzyme linked immunosorbent assay for detection of the peptide have been developed. The presence of the peptide in elevated quantity has been demonstrated in serum of patients with multiple blunt trauma as well as thermally injured patients. It was determined that the peptide is capable of suppressing neutrophil chemotaxis and T-cell blastogenesis as measured by MLR. Inhibition of B-cell blastogenesis induced by the **peptide** as measured by **LPS** mitogen-induced proliferation was demonstrated to be less sensitive to suppression. Further, it appears that activated T lymphocytes, those expressing increased IL-2 receptors, are more sensitive to suppression by the peptide at lower concentrations than are nonactivated T lymphocytes.

=> d his

(FILE 'HOME' ENTERED AT 11:34:20 ON 30 OCT 2000)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, BIOTECHDS, AGRICOLA' ENTERED AT 11:35:33 ON 30 OCT 2000
E PORRO MASSIMO/AU
L1 39 S E3
L2 8 S L1 AND SEPSIS
L3 7 DUP REM L2 (1 DUPLICATE REMOVED)
L4 7 S L1 AND LPS (5A) PEPTIDE
L5 1 S L1 AND GRAM NEGATIVE BACTERIAL INFECT?
L6 157699 S BACTERIAL (5A) INFECT?
L7 50 S L6 AND LPS (5A) PEPTIDE
L8 46 DUP REM L7 (4 DUPLICATES REMOVED)

=> s l6 and lps (10a) synthetic peptid?

L9 8 L6 AND LPS (10A) SYNTHETIC PEPTID?

=> dup rem l9

PROCESSING COMPLETED FOR L9
L10 8 DUP REM L9 (0 DUPLICATES REMOVED)

=> d bib ab 1-8

L10 ANSWER 1 OF 8 USPATFULL
AN 96:120869 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN Porro, Massimo, Siena, Italy
PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)
PI US 5589459 19961231
AI US 1994-280397 19940726 (8)
RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,
Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Davenport, Avis M.
LREP Hedman, Gibson & Costigan, P.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H
or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino
acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.

L10 ANSWER 2 OF 8 USPATFULL
AN 96:5884 USPATFULL
TI Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments
of CAP37
IN Pereira, Heloise A., Decatur, GA, United States
Spitznagel, John K., Decatur, GA, United States
PA Emory University, Atlanta, GA, United States (U.S. corporation)
PI US 5484885 19960116
AI US 1992-855417 19920319 (7)
RLI Continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Furman, Keith C.
LREP Needle & Rosenberg
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 2498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding

sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants of monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.

L10 ANSWER 3 OF 8 USPATFULL
AN 95:92525 USPATFULL
TI Method of increasing monocyte chemotaxis with CAP37 and monocyte chemotactic portions thereof
IN Pereira, Heloise A., Decatur, GA, United States
Spitznagel, John K., Decatur, GA, United States
PA Emory University, Atlanta, GA, United States (U.S. corporation)
PI US 5458874 19951017
AI US 1992-969931 19921030 (7)
RLI Continuation of Ser. No. US 1992-855417, filed on 18 Mar 1992 which is a
continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Furman, Keith C.
LREP Needle & Rosenberg
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 2618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.

L10 ANSWER 4 OF 8 USPATFULL
AN 95:45359 USPATFULL
TI Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
IN Reid, Robert H., Kensington, MD, United States
Boedeker, Edgar C., Chevy Chase, MD, United States
van Hamont, John E., Shape, Belgium
Setterstrom, Jean A., Takoma Park, MD, United States
PA The United States of America as represented by the Secretary of the Army, Washington, DC, United States (U.S. government)
PI US 5417986 19950523
AI US 1992-867301 19920410 (7)
RLI Continuation-in-part of Ser. No. US 1991-805721, filed on 21 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-690485, filed on 24 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-521945, filed on 11 May 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-493597, filed on 15 Mar 1990, now abandoned which is a

continuation-in-part of Ser. No. US 1984-590308, filed on 16 Mar 1984
DT Utility
EXNAM Primary Examiner: Henley, III, Raymond J.; Assistant Examiner: Criares, T. J.
LREP Lane, Anthony T.; Reichert, Earl T.; Bellamy, Werten F. W.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 71 Drawing Figure(s); 70 Drawing Page(s)
LN.CNT 2736
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to oral parenteral and intestinal vaccines and eir use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.

L10 ANSWER 5 OF 8 USPATFULL
AN 94:106884 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN Porro, Massimo, Siena, Italy
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5371186 19941206
AI US 1992-819893 19920116 (7)
DCD 20111025
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel peptides of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the prevention and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L10 ANSWER 6 OF 8 USPATFULL
AN 94:93312 USPATFULL
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
IN Porro, Massimo, Siena, Italy
PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)
PI US 5358933 19941025
AI US 1993-49871 19930419 (8)
RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.
LREP Hedman, Gibson & Costigan
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel peptides are disclosed which are based on the formula:

R.sub.1 (Lys-Phe-Leu).sub.n --R

wherein n is an integer of from 1-10 and R and R.sub.1 are H or an amino acid residue or a fatty acid residue which are useful in the treatment of septic shock.

L10 ANSWER 7 OF 8 USPATFULL
AN 94:82236 USPATFULL
TI Therapeutic uses of bactericidal/permeability increasing protein products
IN Little, II, Roger G., Benicia, CA, United States
Gazzano-Santoro, Helene, San Bruno, CA, United States
Parent, James B., Oakland, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5348942 19940920
AI US 1993-30644 19930312 (8)
DT Utility
EXNAM Primary Examiner: Furman, Keith C.
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 997
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.

L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2000 ACS
AN 1994:94826 CAPLUS
DN 120:94826
TI Unique endotoxin-neutralizing proteins: inhibition of endotoxin-induced tissue factor generation
AU Hirata, Michimasa; Shimomura, Yuko; Yoshida, Masao
CS Sch. Med., Iwate Med. Univ., Morioka, 020, Japan
SO Nippon Kessen Shiketsu Gakkaishi (1993), 4(3), 153-62
CODEN: NKSGEL; ISSN: 0915-7441
DT Journal
LA Japanese
AB Cationic antibacterial proteins (CAP), intracellular lipopolysaccharide (LPS)-binding proteins, were isolated from rabbit peritoneal granulocytes using an assay of the agglutination of erythrocytes coated with Re-LPS. Mol. wt. of CAP estd. by SDS-PAGE was 7 kDa (CAP-7) and 18 kDa (CAP-18), and CAP-7 had high contents of cationic residues. LPS activates murine macrophages and human blood monocytes to generate tissue factor (tissue thromboplastin). After 18 h incubation of LPS prepns. with CAP (heparin-sepharose fraction), S-LPS, Re-LPS and lipid A-induced tissue factor activities were inhibited. S-LPS was inactivated more rapidly than Re-LPS and lipid A. Within 1 h after incubation, purified CAP-18 inhibited about 75% of the activity of S-LPS. CAP-7 also inhibited LPS-induced tissue factor generation by human blood monocytes. LPS-binding, and LPS-neutralizing activities of CAP-7 were higher than those of CAP-18. **Synthetic peptide** #197-1 (having identical structure to CAP-7) also showed **LPS**-binding and LPS-neutralizing activities. Disseminated intravascular coagulation (DIC) manifestation in endotoxemia, due to gram-neg. **bacterial infections**, are controlled by CAP released from granulocytes. In addn., CAP-7 and CAP-18 may have therapeutic potential for septic and endotoxin shock.

```
=> d his

     (FILE 'HOME' ENTERED AT 11:34:20 ON 30 OCT 2000)

     FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS,
     BIOTECHDS, AGRICOLA' ENTERED AT 11:35:33 ON 30 OCT 2000
                E PORRO MASSIMO/AU
L1            39 S E3
L2             8 S L1 AND SEPSIS
L3             7 DUP REM L2 (1 DUPLICATE REMOVED)
L4             7 S L1 AND LPS (5A) PEPTIDE
L5             1 S L1 AND GRAM NEGATIVE BACTERIAL INFECT?
L6        157699 S BACTERIAL (5A) INFECT?
L7            50 S L6 AND LPS (5A) PEPTIDE
L8            46 DUP REM L7 (4 DUPLICATES REMOVED)
L9             8 S L6 AND LPS (10A) SYNTHETIC PEPTID?
L10            8 DUP REM L9 (0 DUPLICATES REMOVED)

=> s l6 and endotox?

L11        4036 L6 AND ENDOTOX?

=> s l11 and lps

L12        1284 L11 AND LPS

=> s l12 and menigitidis

L13           0 L12 AND MENIGITIDIS

=> s l12 and sepsis

L14         476 L12 AND SEPSIS

=> dup rem l14

PROCESSING COMPLETED FOR L14
L15          421 DUP REM L14 (55 DUPLICATES REMOVED)

=> s l14 and synthetic peptid?

L16          48 L14 AND SYNTHETIC PEPTID?

=> dup rem l16

PROCESSING COMPLETED FOR L16
L17           48 DUP REM L16 (0 DUPLICATES REMOVED)

=> d his

     (FILE 'HOME' ENTERED AT 11:34:20 ON 30 OCT 2000)

     FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS,
     BIOTECHDS, AGRICOLA' ENTERED AT 11:35:33 ON 30 OCT 2000
                E PORRO MASSIMO/AU
L1            39 S E3
L2             8 S L1 AND SEPSIS
L3             7 DUP REM L2 (1 DUPLICATE REMOVED)
L4             7 S L1 AND LPS (5A) PEPTIDE
L5             1 S L1 AND GRAM NEGATIVE BACTERIAL INFECT?
L6        157699 S BACTERIAL (5A) INFECT?
```

```
L7            50 S L6 AND LPS (5A) PEPTIDE
L8            46 DUP REM L7 (4 DUPLICATES REMOVED)
L9             8 S L6 AND LPS (10A) SYNTHETIC PEPTID?
L10            8 DUP REM L9 (0 DUPLICATES REMOVED)
L11         4036 S L6 AND ENDOTOX?
L12         1284 S L11 AND LPS
L13            0 S L12 AND MENIGITIDIS
L14          476 S L12 AND SEPSIS
L15          421 DUP REM L14 (55 DUPLICATES REMOVED)
L16           48 S L14 AND SYNTHETIC PEPTID?
L17           48 DUP REM L16 (0 DUPLICATES REMOVED)

=> d bib 1-48


L17  ANSWER 1 OF 48  USPATFULL
AN      2000:109964  USPATFULL
TI      Antimicrobial peptides and methods of use thereof
IN      Pereira, H. Anne, Edmond, OK, United States
PA      The Board of Regents of the University of Oklahoma, Norman, OK, United
        States (U.S. corporation)
PI      US 6107460  20000822
AI      US 1999-258934  19990301 (9)
DT      Utility
EXNAM   Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner:
        Srivastava, Deven
LREP    Dunlap, Codding & Rogers
CLMN    Number of Claims: 5
ECL     Exemplary Claim: 1
DRWN    20 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1073
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17  ANSWER 2 OF 48  USPATFULL
AN      2000:106071  USPATFULL
TI      Mammalian cationic proteins having lipopolysaccharide binding and
        anti-coagulant activity
IN      Larrick, James W., Woodside, CA, United States
        Wright, Susan C., Saratoga, CA, United States
        Hirata, Michimasa, Morioka, Japan
PA      Panorama Research, Inc., Mountain View, CA, United States (U.S.
        corporation)
PI      US 6103888  20000815
AI      US 1999-322911  19990601 (9)
RLI     Continuation of Ser. No. US 1996-691280, filed on 1 Aug 1996 which is a
        continuation-in-part of Ser. No. US 313681
DT      Utility
EXNAM   Primary Examiner: Housel, James C.; Assistant Examiner: Portner, Ginny
        Allen
LREP    Townsend and Townsend and Crew
CLMN    Number of Claims: 1
ECL     Exemplary Claim: 1
DRWN    30 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17  ANSWER 3 OF 48  USPATFULL
AN      2000:94872  USPATFULL
TI      Three-dimensional structure of bactericidal/permeability-increasing
        protein (BPI)
IN      Beamer, Lesa J., Santa Monica, CA, United States
        Carroll, Stephen F., Walnut Creek, CA, United States
        Eisenberg, David, Los Angeles, CA, United States
PA      XOMA, Berkeley, CA, United States (U.S. corporation)
        The Regents of the University of California, Oakland, CA, United States
```

(U.S. corporation)
PI US 6093573 20000725
AI US 1997-879565 19970620 (8)
DT Utility
EXNAM Primary Examiner: Nashed, Nashaat
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 126 Drawing Figure(s); 125 Drawing Page(s)
LN.CNT 2940
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 48 USPATFULL
AN 2000:80408 USPATFULL
TI Compositions for the prevention and treatment of verotoxin-induced disease
IN Williams, James A., Lincoln, NE, United States
Byrne, Lisa Marie, Stoughton, WI, United States
PA Ophidian Pharmaceuticals, Inc., Wisconsin, United States (U.S. corporation)
PI US 6080400 20000627
AI US 1997-816977 19970313 (8)
RLI Continuation-in-part of Ser. No. US 1995-410058, filed on 24 Mar 1995, now abandoned
DT Utility
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Devi, S.
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 5468
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 48 USPATFULL
AN 2000:70809 USPATFULL
TI Method for the treatment of **bacterial infection**
IN Pereira, Heloise Anne, Edmond, OK, United States
PA The Board of Regents of the University of Oklahoma, United States (U.S. corporation)
PI US 6071879 20000606
AI US 1999-260373 19990301 (9)
RLI Continuation of Ser. No. US 1997-840519, filed on 21 Apr 1997, now patented, Pat. No. US 5877151 which is a continuation of Ser. No. US 1995-482328, filed on 7 Jun 1995, now patented, Pat. No. US 5627262, issued on 6 May 1997 which is a continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916 which is a continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US
5484885 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Moore, William W.
LREP Dunlap, Codding & Rogers, P.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 806
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 6 OF 48 USPATFULL
AN 2000:54074 USPATFULL

TI Antimicrobial cationic peptides
IN Hancock, Robert E. W., Vancouver, Canada
Karunaratne, Nedra, Kandy, Sri Lanka
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 6057291 20000502
AI US 1996-763226 19961210 (8)
RLI Continuation-in-part of Ser. No. US 1996-658857, filed on 31 May 1996 which is a continuation-in-part of Ser. No. US 1995-460464, filed on 2 Jun 1995, now patented, Pat. No. US 5877274
DT Utility
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Longton, Enrique D.
LREP Fish & Richardson P. C.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2740
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 7 OF 48 USPATFULL
AN 2000:50681 USPATFULL
TI Anti-gram-positive bacterial methods and materials
IN Horwitz, Arnold, Los Angeles, CA, United States
Lambert, Jr., Lewis H., Fremont, CA, United States
Little, II, Roger G., Benicia, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 6054431 20000425
AI US 1998-119263 19980720 (9)
RLI Continuation of Ser. No. US 1996-758116, filed on 25 Nov 1996, now patented, Pat. No. US 5783561 which is a continuation of Ser. No. US 1995-372783, filed on 13 Jan 1995, now patented, Pat. No. US 5578572 which is a continuation-in-part of Ser. No. US 1994-274299, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-209762, filed on 11 Mar 1994, now patented, Pat. No. US 5733872 which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned
DT Utility
EXNAM Primary Examiner: MacMillan, Keith D.; Assistant Examiner: Ponnalun, P.
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 32 Drawing Page(s)
LN.CNT 6671
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 8 OF 48 USPATFULL
AN 2000:40880 USPATFULL
TI Polynucleotides encoding a cardiotrophin-like cytokine
IN Shi, Yanggu, Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6046035 20000404
AI US 1998-106182 19980629 (9)
PRAI US 1997-51311 19970630 (60)
DT Utility
EXNAM Primary Examiner: Ulm, John; Assistant Examiner: Saoud, Christine
LREP Human Genome Sciences Inc.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 3830
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 9 OF 48 USPATFULL
AN 2000:34679 USPATFULL
TI Antimicrobial cationic peptides
IN Hancock, Robert E. W., Vancouver, Canada
Karunaratne, Nedra, Vancouver, Canada
PA University of British Columbia, Vancover, Canada (non-U.S. corporation)
PI US 6040435 20000321
AI US 1996-658857 19960531 (8)
RLI Continuation-in-part of Ser. No. US 1995-460464, filed on 2 Jun 1995, now patented, Pat. No. US 5877274
DT Utility
EXNAM Primary Examiner: Sisson, Bradley; Assistant Examiner: Longton, Enrique D.
LREP Gary Cary Ware & Freidenrich LLP; Haile, Lisa A.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2069
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 10 OF 48 USPATFULL
AN 2000:34395 USPATFULL
TI Assay for identifying agents which act on the ceramide-activated protein
kinase, kinase suppressor of ras, and methods of using said agents
IN Kolesnick, Richard N., New York, NY, United States
Liu, Jun, Boston, MA, United States
Zhang, Yuhua, New York, NY, United States
PA Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 6040149 20000321
AI US 1997-785247 19970110 (8)
PRAI US 1996-9900 19960111 (60)
DT Utility
EXNAM Primary Examiner: Hobbs, Lisa J.
LREP White, John P.Cooper & Dunham LLP
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 57 Drawing Figure(s); 41 Drawing Page(s)
LN.CNT 4300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 48 USPATFULL
AN 2000:12617 USPATFULL
TI H. influenzae HxuB and HxuC genes, proteins and methods of use
IN Hansen, Eric J., Plano, TX, United States
Cope, Leslie D., Mesquite, TX, United States
Jarosik, Gregory P., Arlington, TX, United States
Hanson, Mark S., Columbia, MD, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6020154 20000201
AI US 1995-425843 19950420 (8)
DT Utility
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Srivastava, Devesh
LREP Arnold, White & Durkee
CLMN Number of Claims: 77
ECL Exemplary Claim: 20
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 4068
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 12 OF 48 USPATFULL
AN 1999:170587 USPATFULL

TI Antimicrobial peptides and methods of use
IN Selsted, Michael E., Irvine, CA, United States
PA The Regents of University of California, Oakland, CA, United States (U.S. corporation)
PI US 6008195 19991228
AI US 1997-799149 19970214 (8)
PRAI US 1996-11834 19960216 (60)
DT Utility
EXNAM Primary Examiner: Prouty, Rebecca E.
LREP Gray Cary Ware & Freidenrich LLP; Haile, Lisa A.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1671
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 13 OF 48 USPATFULL
AN 1999:163462 USPATFULL
TI Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1)
and polypeptides encoded thereby
IN Ruben, Steven M., Olney, MD, United States
Li, Haodong, Gaithersburg, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6001606 19991214
AI US 1996-722719 19960930 (8)
RLI Continuation-in-part of Ser. No. US 1995-446881, filed on 5 May 1995, now abandoned which is a continuation-in-part of Ser. No. US 1995-465682, filed on 6 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-208339, filed on 8 Mar 1994, now patented, Pat. No. US 5504003 Ser. No. Ser. No. US 1995-468775, filed on 6 Jun 1995, now abandoned And Ser. No. WO 1996-US15592, filed on 27 Sep 1996 , said Ser. No. US 465682 which is a continuation-in-part
of Ser. No. US 446881 , said Ser. No. US 468775 which is a continuation-in-part of Ser. No. US 446881
PRAI US 1995-4517 19950929 (60)
DT Utility
EXNAM Primary Examiner: Mertz, Prema
LREP Sterne, Kessler, Goldstein & Fox, P.L.L.C.
CLMN Number of Claims: 74
ECL Exemplary Claim: 1
DRWN 53 Drawing Figure(s); 49 Drawing Page(s)
LN.CNT 6406
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 14 OF 48 USPATFULL
AN 1999:155689 USPATFULL
TI Fine-tuned protegrins
IN Chang, Conway C., San Francisco, CA, United States
Gu, Chee Liang, Saratoga, CA, United States
Chen, Jie, Belmont, CA, United States
Steinberg, Deborah A., Saratoga, CA, United States
Lehrer, Robert I., Santa Monica, CA, United States
Harwig, deceased, Sylvia S.L., late of Woodland Hills, CA, United States
by John Harwig, executor
PA IntraBiotics Pharmaceuticals, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5994306 19991130
AI US 1996-752852 19961121 (8)
RLI Continuation-in-part of Ser. No. US 1996-690921, filed on 1 Aug 1996, now abandoned which is a continuation-in-part of Ser. No. US 1996-649811, filed on 17 May 1996, now abandoned which is a

continuation-in-part of Ser. No. US 1995-562346, filed on 22 Nov 1995, now abandoned which is a continuation-in-part of Ser. No. US 1995-499523, filed on 7 Jul 1995, now patented, Pat. No. US 5804558 which is a continuation-in-part of Ser. No. US 1995-451832, filed on 26 May 1995, now abandoned which is a continuation-in-part of Ser. No. WO 1994-US8305, filed on 20 Jul 1994 And Ser. No. US 1994-243879, filed on 17 May 1994, now patented, Pat. No. US 5708145 which is a continuation-in-part of Ser. No. US 1994-182483, filed on 13 Jan 1994, now patented, Pat. No. US 5693486 which is a continuation-in-part of Ser. No. US 1993-95769, filed on 26 Jul 1993, now patented, Pat. No. US 5464823 which is a continuation-in-part of Ser. No. US 1993-93926, filed
on 20 Jul 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapura; Assistant Examiner: Moore,
William W.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 5488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 15 OF 48 USPATFULL
AN 1999:145984 USPATFULL
TI Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
IN Lowell, George H., 6303 Western Run Dr., Baltimore, MD, United States 21215
PI US 5985284 19991116
AI US 1996-677302 19960709 (8)
RLI Continuation of Ser. No. US 1996-673756, filed on 29 Apr 1996 which is a
continuation of Ser. No. WO 1993-US10402, filed on 29 Oct 1993
DT Utility
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Graser, Jennifer
LREP Morrison & Foerster LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1535
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 16 OF 48 USPATFULL
AN 1999:27732 USPATFULL
TI Antimicrobial cationic peptides
IN Hancock, Robert E. W., Vancouver, Canada
Karunaratne, Nedra, Vancouver, Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 5877274 19990302
AI US 1995-460464 19950602 (8)
DT Utility
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Longton, Enrique D.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 1008
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 17 OF 48 USPATFULL

AN 1999:27610 USPATFULL
TI Method for inhibiting production of tumor necrosis factor
IN Pereira, Heloise Anne, Edmond, OK, United States
PA The Board of Regents of the University of Oklahoma, United States (U.S. corporation)
PI US 5877151 19990302
AI US 1997-840519 19970421 (8)
RLI Continuation of Ser. No. US 1995-482328, filed on 7 Jun 1995, now patented, Pat. No. US 5627262, issued on 6 May 1997 which is a continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916, issued on 4 Mar 1997 which is a continuation-in-part of Ser. No. US 1992-939931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874, issued on 17 Oct 1995 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885, issued on 16 Jan 1996 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.
LREP Dunlap & Codding, P.C.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 804
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 18 OF 48 USPATFULL
AN 1999:1767 USPATFULL
TI Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
IN Little, II, Roger G., Benicia, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5856438 19990105
AI US 1995-485445 19950607 (8)
RLI Continuation of Ser. No. US 1994-306473, filed on 15 Sep 1994, now patented, Pat. No. US 5652332 And a continuation-in-part of Ser. No. US 1994-273540, filed on 11 Jul 1994, now abandoned And Ser. No. US 1994-274299, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-209762, filed on 11 Mar 1994, now patented, Pat. No. US 5696085 which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned , said Ser.
No. US 306473 which is a continuation-in-part of Ser. No. US 209762 , said Ser. No. US 183222 which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility
EXNAM Primary Examiner: Davenport, Avis M.
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 94 Drawing Figure(s); 78 Drawing Page(s)
LN.CNT 5756
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 19 OF 48 USPATFULL
AN 1998:162479 USPATFULL
TI Therapeutic uses of bactericidal/permeability increasing protein products
IN Little, II, Roger G., Benicia, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5854214 19981229
AI US 1995-466826 19950606 (8)

RLI Continuation of Ser. No. US 1995-415158, filed on 31 Mar 1995, now patented, Pat. No. US 5639727 which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility
EXNAM Primary Examiner: Kemmerer, Elizabeth C.; Assistant Examiner: Romeo, David S.
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 31 Drawing Page(s)
LN.CNT 1552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 20 OF 48 USPATFULL
AN 1998:159736 USPATFULL
TI Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
IN Better, Marc D., Los Angeles, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5851802 19981222
AI US 1996-621803 19960322 (8)
DT Utility
EXNAM Primary Examiner: Spector, Lorraine
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 4280
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 21 OF 48 USPATFULL
AN 1998:154080 USPATFULL
TI DNA encoding tumor necrosis factor stimulated gene 6 (TSG-6)
IN Lee, Tae Ho, Daejeon, Korea, Republic of
Wisniewski, Hans-Georg, New York, NY, United States
Vilcek, Jan, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 5846763 19981208
AI US 1994-242097 19940513 (8)
RLI Continuation-in-part of Ser. No. US 1993-24868, filed on 1 Mar 1993, now
patented, Pat. No. US 5386013 which is a continuation of Ser. No. US 1991-642312, filed on 14 Jan 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Draper, Garnette D.; Assistant Examiner: Kemmerer, Elizabeth C.
LREP Browdy and Neimark
CLMN Number of Claims: 14
ECL Exemplary Claim: 2
DRWN 48 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 3807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 22 OF 48 USPATFULL
AN 1998:144206 USPATFULL
TI Polypeptides of lipopolysaccharide binding protein
IN Han, Jiahuai, La Jolla, CA, United States
Ulevitch, Richard J., Del Mar, CA, United States
Tobias, Peter S., San Diego, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 5837810 19981117
AI US 1994-215089 19940315 (8)
DT Utility

EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Johnson, Nancy A.
LREP Fish & Richardson, P.C.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 1162
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 23 OF 48 USPATFULL
AN 1998:144078 USPATFULL
TI Therapeutic uses of bactericidal/permeability increasing protein products
IN Little, II, Roger G., Benicia, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5837678 19981117
AI US 1995-466624 19950606 (8)
RLI Continuation of Ser. No. US 1995-415158, filed on 31 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility
EXNAM Primary Examiner: Jagannathan, Vasu S.; Assistant Examiner: Kim, Hyosuk
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 31 Drawing Page(s)
LN.CNT 1558
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 24 OF 48 USPATFULL
AN 1998:111899 USPATFULL
TI Therapeutic uses of bactericidal/permeability increasing protein (BPI) protein products
IN Little, II, Roger G., Benicia, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5807818 19980915
AI US 1995-435855 19950505 (8)
RLI Division of Ser. No. US 1995-415158, filed on 31 Mar 1995, now patented, Pat. No. US 5639727 which is a continuation of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility
EXNAM Primary Examiner: Kemmerer, Elizabeth C.; Assistant Examiner: Lathrop, Brian
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 31 Drawing Page(s)
LN.CNT 1542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 25 OF 48 USPATFULL
AN 1998:92001 USPATFULL
TI Treatment of **endotoxin**-associated disorders with cationic peptides
IN Hancock, Robert E. W., Vancouver, Canada
Piers, Kevin L., Richmond, Canada
Brown, Melissa H., Vancouver, Canada
Kelly, Niamh, Vancouver, Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 5789377 19980804

AI US 1995-405234 19950313 (8)
RLI Continuation-in-part of Ser. No. US 1993-110502, filed on 20 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-933492, filed on 21 Aug 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Fish & Richardson, P.C.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 24 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 1454
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 26 OF 48 USPATFULL
AN 1998:85936 USPATFULL
TI Anti-gram-positive bacterial methods and materials
IN Horwitz, Arnold, Los Angeles, CA, United States
Lambert, Jr., Lewis H., Fremont, CA, United States
Little, II, Roger G., Benicia, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5783561 19980721
AI US 1996-758116 19961125 (8)
RLI Continuation of Ser. No. US 1995-372783, filed on 13 Jan 1995, now patented, Pat. No. US 5578572 which is a continuation-in-part of Ser. No. US 1994-274299, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-209762, filed on 11 Mar 1994, now patented, Pat. No. US 5733872 which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapura
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 32 Drawing Page(s)
LN.CNT 6127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 27 OF 48 USPATFULL
AN 1998:82718 USPATFULL
TI Anti-**LPS** factor from horseshoe crabs and methods of use
IN Wainwright, Norman R., Falmouth, MA, United States
PA Marine Biological Laboratory, Woods Hole, MA, United States (U.S. corporation)
PI US 5780429 19980714
AI US 1995-577464 19951222 (8)
DT Utility
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Hale and Dorr LLP
CLMN Number of Claims: 6
ECL Exemplary Claim: 4
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 843
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 28 OF 48 USPATFULL
AN 1998:72434 USPATFULL
TI DNA encoding macrophage inflammatory protein-1.gamma.
IN Beutler, Bruce A., Dallas, TX, United States
Poltorak, Alexander N., Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5770402 19980623
AI US 1995-418032 19950405 (8)
DT Utility

EXNAM Primary Examiner: Ulm, John; Assistant Examiner: Mertz, Prema
LREP Arnold, White & Durkee
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 29 OF 48 USPATFULL
AN 1998:65346 USPATFULL
TI Biologically active peptides from funcional domains of bactericidal/permeability-increasing protein and uses thereof
IN Little, Roger G., Benicia, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5763567 19980609
AI US 1995-473344 19950607 (8)
RLI Continuation of Ser. No. US 1994-209762, filed on 11 Mar 1994 which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility
EXNAM Primary Examiner: Carlson, Karen C.
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 86 Drawing Figure(s); 70 Drawing Page(s)
LN.CNT 3868
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 30 OF 48 USPATFULL
AN 1998:48450 USPATFULL
TI Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
IN Lai, Ching-San, Encinitas, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5747532 19980505
AI US 1995-561594 19951121 (8)
DT Utility
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Smith, Lyman H.
LREP Gray Cary Ware & Freidenrich; Reiter, Stephen E.
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1112
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 31 OF 48 USPATFULL
AN 1998:33895 USPATFULL
TI Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
IN Little, Roger G., Benicia, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5733872 19980331
AI US 1994-209762 19940311 (8)
RLI Continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644, filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility

EXNAM Primary Examiner: Carlson, Karen C.
LREP McAndrews, Held & Malloy, Ltd.
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 86 Drawing Figure(s); 70 Drawing Page(s)
LN.CNT 3967
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 32 OF 48 USPATFULL
AN 1998:31119 USPATFULL
TI Lipopolysaccharide binding protein derivatives
IN Gazzano-Santoro, Helene, San Bruno, CA, United States
Theofan, Georgia, Torrance, CA, United States
Trown, Patrick W., Danville, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5731415 19980324
AI US 1994-261660 19940617 (8)
RLI Continuation-in-part of Ser. No. US 1993-79510, filed on 17 Jun 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Jagannathan, Vasu S.; Assistant Examiner: Romeo, David
S.
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 25 Drawing Page(s)
LN.CNT 2186
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 33 OF 48 USPATFULL
AN 97:107054 USPATFULL
TI Treatment of **endotoxin**-associated disorders with cationic peptides
IN Hancock, Robert E. W., Vancouver, Canada
Piers, Kevin L., Red Deer, Canada
Brown, Melissa H., Canterbury, Australia
Kelly, Niamh, Vancouver, Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 5688767 19971118
AI US 1996-614516 19960313 (8)
RLI Division of Ser. No. US 1995-405234, filed on 13 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-110502, filed on 20 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-933492, filed on 21 Aug 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Patterson, Jr, Charles L.
LREP Fish & Richardson, P.C.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 1709
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 34 OF 48 USPATFULL
AN 97:51974 USPATFULL
TI Therapeutic uses of bactericidal/permeability increasing protein products
IN Little, II, Roger G., Benicia, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5639727 19970617
AI US 1995-415158 19950331 (8)
RLI Continuation of Ser. No. US 1993-93202, filed on 15 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-30644,

filed on 12 Mar 1993, now patented, Pat. No. US 5348942
DT Utility
EXNAM Primary Examiner: Patterson, Jr., Charles L.; Assistant Examiner: Kim, Hydsuk
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 31 Drawing Page(s)
LN.CNT 1570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 35 OF 48 USPATFULL
AN 97:38605 USPATFULL
TI Method and composition for the treatment of septic shock
IN Pereira, Heloise A., Edmond, OK, United States
PA The Board of Regents of the University of Oklahoma, Norman, OK, United States (U.S. corporation)
PI US 5627262 19970506
AI US 1995-482328 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-235399, filed on 29 Apr 1994, now patented, Pat. No. US 5607916, issued on 4 Mar 1997 which is a continuation-in-part of Ser. No. US 1992-969931, filed on 30 Oct 1992, now patented, Pat. No. US 5458874, issued on 17 Oct 1995 which is a continuation of Ser. No. US 1992-855417, filed on 19 Mar 1992, now patented, Pat. No. US 5484885, issued on 16 Jan 1996 which is a continuation-in-part of Ser. No. US 1990-543151, filed on 25 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-375739, filed on 5 Jul 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Moore, William W.
LREP Dunlap & Codding, P.C.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 36 OF 48 USPATFULL
AN 97:29335 USPATFULL
TI Methods and compositions for detecting lipopolysaccharides using CAP18 fragments
IN Larrick, James W., Woodside, CA, United States
Wright, Susan C., Saratoga, CA, United States
PA Panorama Research, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5618675 19970408
AI US 1994-313681 19940927 (8)
RLI Continuation-in-part of Ser. No. US 1992-916961, filed on 16 Jul 1992, now patented, Pat. No. US 5277707 And Ser. No. US 1992-916765, filed on 17 Jul 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Portner, Ginny Allen
LREP Townsend & Townsend & Crew LLP
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 1963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 37 OF 48 USPATFULL
AN 97:25018 USPATFULL
TI Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
IN Hadden, John W., Tampa, FL, United States

Giner-Sorolla, Alfredo, Tampa, FL, United States
PA The University of South Florida, Tampa, FL, United States (U.S. corporation)
PI US 5614504 19970325
AI US 1995-426682 19950421 (8)
RLI Continuation-in-part of Ser. No. US 1992-995550, filed on 22 Dec 1992, now abandoned which is a continuation of Ser. No. US 1990-561979, filed on 1 Aug 1990, now abandoned
DT Utility
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Crane, L. Eric
LREP Kohn & Associates
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 38 OF 48 USPATFULL
AN 97:7685 USPATFULL
TI Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
IN Kamireddy, Balreddy, Hockessin, DE, United States
Darsley, Michael J., Rockville, MD, United States
Simpson, David M., Adelphi, MD, United States
Massey, Richard J., Rockville, MD, United States
PA Igen, Inc., Gaithersburg, MD, United States (U.S. corporation)
PI US 5597573 19970128
AI US 1995-405438 19950314 (8)
RLI Continuation-in-part of Ser. No. US 1991-761868, filed on 3 Sep 1991
And
a continuation-in-part of Ser. No. US 1993-37261, filed on 26 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-871229, filed on 17 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-861362, filed on 27 Mar 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Kim, Kay K. A.
LREP Curtis, Morris & Safford; Evans, Barry; Salkeld, Pamela G.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 53 Drawing Figure(s); 53 Drawing Page(s)
LN.CNT 4095
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 39 OF 48 USPATFULL
AN 97:3817 USPATFULL
TI Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
IN Kamireddy, Balreddy, Rockville, MD, United States
Darsley, Michael J., Rockville, MD, United States
Simpson, David M., Adelphi, MD, United States
Massey, Richard J., Rockville, MD, United States
PA IGEN Incorporated, Gaithersburg, MD, United States (U.S. corporation)
PI US 5593969 19970114
AI US 1993-123590 19930917 (8)
RLI Continuation of Ser. No. US 1992-871229, filed on 17 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-861362, filed on 27 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-761868, filed on 3 Sep 1991
DT Utility
EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Fonda, Kathleen Kahler
LREP Curtis, Morris & Safford; Evans, Barry; Salkeld, Pamela G.
CLMN Number of Claims: 4

ECL Exemplary Claim: 1
DRWN 47 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 4116
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 40 OF 48 USPATFULL
AN 96:108941 USPATFULL
TI Anti-gram-positive bacterial methods and materials
IN Horwitz, Arnold, Los Angeles, CA, United States
Lambert, Jr., Lewis H., Fremont, CA, United States
Little, II, Roger G., Benicia, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5578572 19961126
AI US 1995-372783 19950113 (8)
RLI Continuation-in-part of Ser. No. US 1994-274299, filed on 11 Jul 1994 which is a continuation-in-part of Ser. No. US 1994-209762, filed on 11 Mar 1994 which is a continuation-in-part of Ser. No. US 1994-183222, filed on 14 Jan 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapura
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 32 Drawing Page(s)
LN.CNT 4639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 41 OF 48 USPATFULL
AN 95:69093 USPATFULL
TI Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
IN Edgington, Thomas S., La Jolla, CA, United States
Colman, Robert W., Moylan, PA, United States
Kappelmayer, Janos, Debrecen, Hungary
Edmunds, Jr., L. Henry, Bryn Mawr, PA, United States
Bernabei, Alvise, Philadelphia, PA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
Trustees of the University of Pennsylvania, Phialdelphia, PA, United States (U.S. corporation)
Temple University - Of the Commonwealth Systems of Higher Education, Phialdelphia, PA, United States (U.S. corporation)
PI US 5437864 19950801
AI US 1992-977281 19921116 (7)
RLI Continuation-in-part of Ser. No. US 1988-165939, filed on 9 Mar 1988, now patented, Pat. No. US 5223427 which is a continuation-in-part of Ser. No. US 1987-67103, filed on 25 Jun 1987, now patented, Pat. No. US 5110730 which is a continuation-in-part of Ser. No. US 1987-33047, filed
on 31 Mar 1987, now abandoned
DT Utility
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Cunningham, T.
LREP Spensley Horn Jubas & Lubitz
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 3505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 42 OF 48 USPATFULL
AN 95:54452 USPATFULL
TI DNA encoding cytokine-induced protein, TSG-14
IN Lee, Tae H., Cambridge, MA, United States
Lee, Gene W., New York, NY, United States

Vilcek, Jan, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 5426181 19950620
AI US 1992-929580 19920814 (7)
RLI Continuation of Ser. No. US 1991-640492, filed on 14 Jan 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Draper, Garnette D.; Assistant Examiner: Kemmerer, Elizabeth C.
LREP Browdy and Neimark
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 36 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 3175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 43 OF 48 USPATFULL
AN 95:9803 USPATFULL
TI Tumor necrosis factor-induced protein TSG-6
IN Lee, Tae H., Piscataway, NJ, United States
Wisniewski, Hans-Georg, Spring Valley, NY, United States
Vilcek, Jan, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 5386013 19950131
AI US 1993-24868 19930301 (8)
RLI Continuation of Ser. No. US 1991-642312, filed on 14 Jan 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Draper, Garnette D.; Assistant Examiner: Kemmerer, Elizabeth C.
LREP Browdy and Neimark
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 50 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 2952
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 44 OF 48 USPATFULL
AN 94:82236 USPATFULL
TI Therapeutic uses of bactericidal/permeability increasing protein products
IN Little, II, Roger G., Benicia, CA, United States
Gazzano-Santoro, Helene, San Bruno, CA, United States
Parent, James B., Oakland, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5348942 19940920
AI US 1993-30644 19930312 (8)
DT Utility
EXNAM Primary Examiner: Furman, Keith C.
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 997
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 45 OF 48 USPATFULL
AN 94:66475 USPATFULL
TI Recombinant, non-glycosylated bpi protein and uses thereof
IN Scott, Randal W., Cupertino, CA, United States
Marra, Marian N., San Mateo, CA, United States
PA INCYTE Pharamaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5334584 19940802
AI US 1992-990044 19921214 (7)

DCD 20090218
RLI Continuation of Ser. No. US 1991-681551, filed on 5 Apr 1991, now patented, Pat. No. US 5171739 which is a continuation-in-part of Ser. No. US 1990-567016, filed on 13 Aug 1990 which is a continuation-in-part of Ser. No. US 1990-468696, filed on 19 Jan 1990, now patented, Pat. No. US 5089274 which is a continuation-in-part of Ser. No. US 1989-310842, filed on 14 Feb 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Wityshyn, Michael G.; Assistant Examiner: Koh, Choon P.
LREP White, John P.
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 53 Drawing Figure(s); 53 Drawing Page(s)
LN.CNT 2041
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 46 OF 48 USPATFULL
AN 94:37931 USPATFULL
TI Treatment of **endotoxin**-associated shock and prevention thereof using a BPI protein
IN Scott, Randal W., Cupertino, CA, United States
Marra, Marian N., San Mateo, CA, United States
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5308834 19940503
AI US 1992-990662 19921214 (7)
DCD 20091215
RLI Division of Ser. No. US 1991-681551, filed on 5 Apr 1991, now patented, Pat. No. US 5171739 which is a continuation-in-part of Ser. No. US 1990-567016, filed on 13 Aug 1990 which is a continuation-in-part of Ser. No. US 1990-468696, filed on 22 Jan 1990, now patented, Pat. No. US 5089274 which is a continuation-in-part of Ser. No. US 1989-310842, filed on 14 Feb 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Wityshyn, Michael G.; Assistant Examiner: Koh, Choon
LREP White, John P.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 45 Drawing Figure(s); 53 Drawing Page(s)
LN.CNT 1924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 47 OF 48 USPATFULL
AN 93:22623 USPATFULL
TI Recombinant vectors for Haemophilus influenzae peptides and proteins
IN Anilionis, Algis, Pittsford, NY, United States
Seid, Jr., Robert C., San Francisco, CA, United States
Deich, Robert A., Rochester, NY, United States
Zlotnick, Gary W., Penfield, NY, United States
Green, Bruce A., Pittsford, NY, United States
PA Praxis Biologics, Inc., Rochester, NY, United States (U.S. corporation)
PI US 5196338 19930323
AI US 1990-480396 19900215 (7)
RLI Division of Ser. No. US 1989-396572, filed on 21 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-239572, filed on 1 Sep 1988, now patented, Pat. No. US 5098997 which is a continuation-in-part of Ser. No. US 1987-132073, filed on 11 Dec 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-20849, filed on 2 Mar 1987, now abandoned which is a continuation-in-part of

Ser. No. US 1986-948364, filed on 31 Dec 1986, now abandoned
DT Utility
EXNAM Primary Examiner: Lacey, David L.; Assistant Examiner: Ulm, John D.
LREP Gordon, Alan M.; Baldwin, Geraldine F.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 38 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 3534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 48 OF 48 USPATFULL
AN 92:103053 USPATFULL
TI Treatment of **endotoxin**-associated shock and preventation thereof using a BPI protein
IN Scott, Randal W., Cupertino, CA, United States
Marra, Marian N., San Mateo, CA, United States
PA Incyte Pharmaceuticals, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5171739 19921215
AI US 1991-681551 19910405 (7)
DCD 20090218
RLI Continuation-in-part of Ser. No. US 1990-567016, filed on 13 Aug 1990 which is a continuation-in-part of Ser. No. US 1990-468696, filed on 22 Jan 1990, now patented, Pat. No. US 5089274 which is a continuation-in-part of Ser. No. US 1989-310842, filed on 14 Feb 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Cashion, Jr., Merrell C.; Assistant Examiner: Koh, Choon P.
LREP White, John P.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 51 Drawing Figure(s); 51 Drawing Page(s)
LN.CNT 1654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.